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Abstract
Daptomycin is an important lipopeptide antibiotic used for treating severe infections caused
by Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and
vancomycin-resistant Enterococcus species. Its bactericidal activity requires calcium and the
presence of phosphatidylglycerol (PG) in the target membrane and correlates with membrane
depolarization. Daptomycin has also been shown to form oligomers on target membranes.
Based on these findings, it has been proposed that the bactericidal effect of daptomycin arises
from the formation of oligomeric pores or channels. This thesis reports experiments that test
and further characterize this proposed mode of action.
In the first project, reported in chapter 2, it is demonstrated that oligomer formation is nec-
essary for the bactericidal effect. The semisynthetic lipopeptide CB-182,462, which is similar
to daptomycin in terms of structure and activity, was mixed with daptomycin. Fluorescence
energy transfer studies showed that this mixture indeed produces stable hybrid oligomers, but
at the same time, it was found that the mixture produces a significantly less than additive an-
tibacterial effect. The existence of functionally impaired oligomers indicates that oligomer
formation is indeed important for antibacterial function. However, it also shows that oligomer-
ization is not sufficient; once formed, the oligomers must take another step in order to acquire
antibacterial activity.
The assumption that daptomycin forms channels or pores in the target membranes is based
on the observation that it induces bacterial cell membrane depolarization. However, these
channels or pores have not been shown in a simple membrane model system. In the second
project, a liposome model was used to detect and characterize the permeability properties of
the daptomycin pores. These pores are selective for cations and allow for a higher permeating
rate for smaller ions. Among all the tested cations, Na+ and K+ have the highest permeation
rate, which suggests the in vivo depolarization is mainly due to sodium influx.
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Genetic studies have indicated that an increased content of cardiolipin in the bacterial mem-
brane may contribute to bacterial resistance against the drug. In the third project, it was shown
that daptomycin no longer forms pores, even though it could still form oligomers, when 10
or 20 molar % cardiolipin were included in otherwise susceptible liposomal membranes. The
oligomers formed on cardiolipin-containing membranes had approximately half the number of
subunits (n≈ 4) of their pore-forming counterparts, and they were confined to the outer leaflets
of the membranes. These findings not only reaffirm the suggestion raised in the first project
that oligomerization is not quite enough, but also lead to a more detailed model: daptomycin
first formes tetramers on the outer leaflet before being translocated to the inner leaflet, then two
tetramers on the opposite leaflets align to create an octameric pore. Cardiolipin may mediate
resistance to daptomycin by preventing its membrane translocation and subsequent permeabi-
lization.
iv
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Chapter 1
Introduction
While microbes have been in existence for much longer than humanity, microbes were un-
known to us until the 1670s, when Dutch scientist Antonie van Leeuwenhoek first observed
live microorganisms in water using his home-built microscope. His remarkable work can be
considered the beginning of microbiology. About two centuries later, the breakthrough studies
by Louis Pasteur and Robert Koch led to the establishment of microbiology as an exact sci-
ence, and they also let us realize that, whether we like them or not, microbes play a role in
many aspects of our own lives.
Pasteur first showed that yeast can bring about food fermentation, one of the many things
we like about microbes today. Besides the production of good cheese and wine, microbes
also play a crucial role in maintaining our ecosystem. They also benefit us in many modern
applications such as drug development, waste remediation, and energy generation. On the other
hand, we have every reason to dislike or be afraid of them. Pasteur discovered that bacteria
could cause food spoilage. Soon after, Robert Koch showed that anthrax is caused by Bacillus
anthracis, thus providing the first evidence bacteria can cause disease in man. Infections caused
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by pathogenic microbes have claimed, and continue to claim, more human lives than any other
cause of death. A great number of these pathogens are from the kingdom of bacteria.
The discoveries by Pasteur, Koch, and others enabled us to combat bacterial infections
through hygiene, vaccines, and antibiotic chemotherapy. While antibiotics have been used to
great success for several decades, their utility is diminishing, as bacterial resistance continues
to emerge and spread. Renewed research into the discovery, characterization, and optimization
of antibiotics is therefore imperative.
This chapter will first present a brief up-to-date review of major antibacterial agents. We
will consider both how they attack bacteria, and how the bacteria fight back against them.
Daptomycin, a lipopeptide antibiotic that is the main topic of this thesis, will be introduced in
Section 1.4. The subsequent chapters will present my experimental work on the action mode
of this antibiotic.
1.1 THE ARMS RACE AGAINST BACTERIA
Although written records and archaeological discoveries indicate that we have a very long
history of using antibacterial medicine, all early applications were empirical and met with
limited success.15, 39, 43, 150 The extent of bacterial infection was never under control, and we
can call this period the pre-antibacterial era.
It was not until around 1900 that Paul Ehrlich introduced the concept of a “magic bullet”,
meaning a compound that could selectively target a pathogenic microbe but not its host. Fol-
lowing this concept, Ehrlich and colleagues started the first large-scale drug screening, which
eventually led to the discovery of the anti-syphilis drug Salvarsan (arsphenamine) in 1909.
Using the same approach, Prontosil (sulfamidochrysoidine), the first sulfonamide drug, was
developed and used clinically to treat a wide range of bacteria beginning in the 1930s. In the
meantime, a serendipitous incident happened in Fleming’s lab in 1928, which led to the discov-
ery of penicillin and its clinical use beginning in the early 1940s.7, 69, 160 With the introduction
of these three drugs, the antibiotic era had begun.
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In the following years, a variety of successful antibacterial drugs were obtained from dif-
ferent sources. Some of them are chemically synthesized, just as Salvarsan and Prontosil had
been. The rest of them are antibiotics that are either naturally produced by microorganisms,
such as penicillin by the fungus Penicillium notatum, or are the semisynthetic derivatives of
such natural compounds. With these drugs in hand, humans seemed to get the upper hand in
the war against bacteria. But instead of surrendering, the bacteria came up with biochemical
mechanisms of resistance to these drugs. Therefore, newer and more powerful antibacterial
drugs are constantly required, which means that we have entered a perpetual arms race against
bacteria.
1.1.1 The antibiotic era: Golden age and crisis
After realizing the tremendous healing power of antibacterial chemotherapy, vast resources
were put into the search for more and better antibacterial drugs. The efforts paid off, as a
great number of new drug classes were soon discovered. In retrospect, most of the antibiotic
classes we know today were discovered in the two decades following the clinical introduction
of penicillin, and this period is also considered as the “Golden age” of antibiotics. Silver182
has summarized them all in a discovery timeline (Figure 1.1).
After the “Golden age”, antibiotic discovery entered a protracted period of drought, dur-
ing which only a few new drug classes were discovered. Silver has termed this period the
“Discovery void”. Several factors contributed to this dearth of discoveries:
1. Most of the antibacterials are natural products that were discovered through empirical
screening. After a while, the low-hanging fruit had been harvested, and screening costs
increased.
2. Modification of existing drugs promises more immediate results and financial returns,
while requiring less resources, and therefore came to be preferred over new discovery.
3. Big pharmaceutical companies abandoned the development of antibacterials, focusing
their resources instead on potentially more profitable therapeutic areas.182
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Figure 1.1 The development in antibacterial agents. The dates shown are of their initial discoveries.
Each agent represents a new drug class.182
For several decades, this decrease in development activity remained under the radar and
did not cause much concern. However, the situation has since deteriorated. Antibacterials are
mass-produced and widely distributed for use not only health care, but also in other fields,
mainly in animal husbandry. Under the enormous selection pressure exerted by ubiquitous an-
tibiotics, bacteria started developing different means to adapt and survive. It soon became very
clear that the question was not if bacteria would become resistant to a new drug, but only how
long it will take them to do it. Due to the severity and prevalence of antibacterial resistance,
many infections that until recently could be considered manageable have again become poten-
tially life-threatening. Therefore, we are now facing a renewed crisis of bacterial infections.33
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1.2 ACTION MODES OF ANTIBACTERIAL AGENTS
To overcome this crisis, it is obvious that we have to keep upgrading our antibacterial arsenal.
And hence it is worthwhile to learn lessons from our existing drugs. In this section, I will use
the targets as the focal points to explain the mechanisms of action (MOA) of different drug
classes mentioned in Silver’s timeline (Figure 1.1).
A safe antibacterial agent needs to have very selective toxicity towards bacteria but not its
host organism, which means it needs to act upon a target that is specific for the bacteria. Many
drugs that meet this criterion find their targets in the synthesis the bacterial cell wall or in the
biosynthesis of DNA, RNA, and protein.
1.2.1 Inhibition of murein synthesis
The cell wall of bacteria is an essential structure for their viability and is also the first obstacle
that any antibacterial drug has to deal with before exerting its activity. In contrast to mam-
malian cells, all bacteria other than mycoplasmas have a murein (peptidoglycan) layer on top
of their cytoplasmic membrane. Many antibacterial drugs take advantage of this difference by
inhibiting the biosynthesis of murein at various steps (Figure 1.2). This is a length pathway
with multiple enzyme-catalyzed reactions, as follows:
Synthesis of N-acetylmuramic acid from N-acetylglucosamine. The basic building block N-
acetylglucosamine (GlcNAc) is converted to N-acetyl-muramic acid (MurNAc) by the enzyme
UDP-GlcNAc enolpyruvate transferase (MurA), which transfers enolpyruvate from phospho-
enolpyruvate (PEP) to GlcNAc. Fosfomycin is structurally similar to both glycerophosphate
and PEP (Figure 1.3). Due to the former similarity, fosfomycin is picked up and transported
across the membrane by the glycerophosphate transporter. Inside the cell, fosfomycin behaves
as an antimetabolite of PEP. It attaches covalently to the active site of enzyme MurA, causing
its inactivation.26, 97, 160
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Figure 1.2 Murein biosynthesis is inhibited at various steps by antibacterial agents. The intracel-
lular synthesis of lipid II is carried out in steps 1–5. GlcNAc is first converted to MurNAc by the
enzyme MurA using the substrate phosphoenolpyruvate (PEP). This is followed by the stepwise
addition of a pentapeptide that includes two D-alanine (D-Ala) residues. Fosfomycin and cycloser-
ine are antimetabolites to PEP and D-Ala, respectively, and inhibit these first two steps. In step 3,
MurNAc is further activated and transferred to an undecaprenol phosphate lipid carrier by MraY.
Amphomycin inhibits this step by binding and sequestering the carrier lipid. In step 4, GlcNAc is
added to the carrier-bound MurNAc, whose peptide moiety is further extended in step 5 with pen-
taglycine to form lipid II. In step 6, lipid II is flipped to the outer leaflet of the cytoplasmic membrane,
where the polymerization begins. The glycopeptide moiety is transferred from lipid II to a nascent
peptidoglycan strand by transglycosylase in step 7a, which can be inhibited by moenomycin. Mean-
while, the undecaprenol bisphosphate carrier is converted back to the monophosphate and returns
to the cytosol for the next cycle. Bacitracin inhibits the regeneration of undecaprenol phosphate and
thereby affects step 3 in the next cycle. In the final step, adjacent peptidoglycan strands are cross-
linked via their side peptide chains by transpeptidase. This step can be inhibited by vancomycin
and by β -lactam antibiotics.
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Figure 1.3 Structures of fosfomycin and of its related metabolites. The antibacterial activity of
fosfomycin is due to its structural similarity with the metabolites PEP and glycerophosphate. Prior to
reaching its cytoplasmic enzyme target MurA, fosfomycin is first transported across the cytoplasmic
membrane by the glycerophosphate transporter. Inside the cell, fosfomycin deactivates MurA by
attaching to its active site.160
Attachment of a pentapeptide to MurNAc. A pentapeptide that contains two D-alanine residues
at its free end is added to MurNAc. This pentapeptide is crucial for the cross-linking of adja-
cent murein strands in the final step 8 of murein synthesis. The D-alanine that is part of this
peptide is supplied by alanine racemase and ligated by D-alanine ligase. Cycloserine is an
antimetabolite of D-alanine that can effectively inhibit both enzymes (Figure 1.4).66, 154, 160, 212
Attachment of peptidyl-MurNAc to undecaprenol phosphate. The new building block is trans-
ferred to undecaprenol phosphate, a carrier lipid, by phospho-MurNAc-pentapeptide translo-
case (MraY). This step is inhibited by the lipopeptide antibiotic amphomycin. Unlike the
previous two drugs, which interact directly with enzyme molecules, amphomycin binds to the
lipid carrier substrate. It is worth noting that, while amphomycin is structurally quite similar to
daptomycin (see Figure 1.16), the two antibiotics have very different action modes.35, 169, 200
Completion of the lipid II precursor. The activated building block is extended with another
GlcNAc moiety, which is followed by the addition of a pentapeptide containing only glycine
residues. This glycine pentapeptide is attached to a lysine, which is the third amino acid residue
on the pentapeptide previously attached in step 2. This step completes the synthesis of lipid II.
Transport of lipid II to the outer membrane leaflet. The cytoplasmic lipid II is flipped across the
membrane for the final stage of murein assembly. The exact mechanism involved in translo-
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Figure 1.4 Structures of cycloserine and of its related metabolites. Cycloserine is an antimetabolite
of D-alanine. It inhibits both alanine racemase and D-alanine ligase.160
cation of lipid II across membrane has been studied by many researchers, yet it still remains
controversial. Protein transporters FtsW and MurJ are the two potential candidates that have
been investigated in great detail and debated between two research groups.139, 178, 223
Transfer of the precursor to a nascent murein strand. The glycopeptide moiety of lipid II is
transferred to a nascent murein strand by transglycosylase; this leaves behind the carrier lipid
as a diphosphate. Moenomycin, a glycolipid antibiotic, is the only known antibiotic to inhibit
this step; it binds and inactivates the enzyme.156, 224
The undecaprenol diphosphate carrier released by the transglycosylase reaction is converted
back to undecaprenol phosphate by a pyrophosphatase; it is then flipped back across the mem-
brane to join step 3 of the subsequent cycle. Undecaprenol pyrophosphatase is inhibited by
bacitracin, which sequesters the carrier lipid in the outer membrane leaflet. This indirectly
inhibits step 3.191–193
Covalent cross-linking of murein strands. Adjacent murein strands are cross-linked to form
the final murein mesh structure. The cross-linking reaction takes place between the termi-
nal residue of the pentaglycine of one strand and the subterminal D-alanine residue of another;
the terminal D-alanine residue is released in the process. This enzymatic reaction can be in-
hibited by vancomycin, which binds to the D-Ala-D-Ala peptide substrate denies it access to
the active site of the transpeptidase. It is also inhibited by β -lactam antibiotics, which include
8
1 Introduction
the penicillins, cephalosporins, carbapenems, and monobactams. These antibiotics have struc-
tural similarity with the D-Ala-D-Ala peptide moiety. Moreover, the β -lactam ring is “spring-
loaded” and is ready to react covalently with the transpeptidase, which can inhibit the enzyme
function completely.160, 205, 213
1.2.2 Inhibition of mycolic acid synthesis
Isoniazid (isonicotinic acid hydrazide) is one drug specifically used for tuberculosis treatment.
It targets cell wall synthesis as well. However, instead of attacking any of the steps involved in
murein synthesis, it targets the synthesis of mycolic acids. Mycolic acids are fatty acids with
very long chains that are precursors for constructing the unique cell wall of mycobacteria, a
class of pathogenic bacteria that includes the causative agent of tuberculosis. Isoniazid is a
prodrug; it is first activated by the mycobacterial catalase-peroxidase KatG to form an isonico-
tinic acid radical. The radical then forms an adduct with NAD+ that inhibits the enzyme InhA,
which in turn is directly involved in mycolic acid synthesis.160, 204
1.2.3 Inhibition of ribosomal protein synthesis
Protein synthesis is another major target exploited by many classes of antibacterial agents (Fig-
ure 1.5). The ribosomes of bacteria and of eukaryotes differ significantly in size and structure.
The bacterial ribosome has a sedimentation velocity of 70S; it consists of a large (50S) subunit
and a small (30S) subunit. In contrast, the eukaryotic ribosome has 80S with subunits of 60S
and 40S, respectively. Some antibiotics, for example puromycin, inhibit both the eukaryotic
and the prokaryotic ribosome; however, many others selectively inhibit the bacterial ribosome
and are therefore useful in antibacterial chemotherapy.
Most drugs that target the ribosome bind to the 23S ribosomal RNA (rRNA) molecule,
which is part of the large 50S subunit and contains the peptidyl transferase active site.173 These
drugs include chloramphenicol, pleuromutilin, erythromycin, lincomycin, and streptogramin.
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Figure 1.5 Inhibition of bacterial ribosomal protein biosynthesis. Most of the antibiotics that bind to
the 50S subunit interfere with the extension of the peptide. An exception are the oxazolidinone an-
tibiotics, which inhibit the initiation of translation. The antibiotics chlortetracycline and streptomycin
bind to the 30S subunit and interact with A-site; they interfere with the binding and the proofreading
of the tRNA, respectively. Fusidic acid binds to elongation factor G (EF-G) and stops translocation
of peptidyl-tRNA from the aminoacyl-site (A-site) to the peptidyl-site (P-site). Puromycin acts as a
false aminoacyl-tRNA, which terminates the peptide extension. Mupirocin inhibits the synthesis of
isoleucyl-tRNA.
Peptidyl transferase is responsible for elongating the nascent peptide with an incoming amino
acid by catalyzing the formation of a peptide bond.
Erythromycin, lincomycin, and streptogramin belong to the drug classes of macrolides, lin-
cosamides, and streptogramins, respectively. While these three drug classes have very different
chemical structures, they are nevertheless often grouped together as the MLS antibiotics be-
cause of their very similar binding sites and action mechanisms. This similarity also accounts
for their notorious cross-resistance (Section1.3.1). The binding of these drugs to the peptidyl
transferase active site interferes with the binding of incoming aminoacyl-tRNA to the A-site of
the ribosome, which subsequently inhibits the formation of a new peptide bond and forces the
premature release of peptidyl-tRNA.121, 138, 168, 202
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Oxazolidinones are another class of drugs that bind to 23S rRNA on the 50S subunit and
even compete for the binding site with chloramphenicol and lincomycin.115, 219 They also
inhibit peptide synthesis, but this effect is mechanistically distinct from the other 50S-bound
inhibitors. Unlike the others, which act on a growing peptide, oxazolidinones prevent the
translation right from the start by inhibiting the formation of the ternary initiation complex
between N-formylmethionyl-tRNA, the ribosome, and mRNA.162, 181, 198
Despite the great similarity of activity shared among all of these 23S rRNA targeting drugs,
structural and resistance studies have shown that there were still some subtle differences in their
exact mechanisms of action.216
There are fewer drug classes that bind to the 30S subunit, but there is a great diversity in
their mechanisms of action. Example of such drugs include streptomycin, chlortetracycline,
and fusidic acid. Streptomycin, an aminoglycoside, interacts with the aminoacyl-site or A-site,
where tRNA binding to the ribosome and pairing with mRNA take place. The A-site serves
as the proofreader for mRNA translation; it ensures that only the correct tRNA-mRNA pairs
will form. The interaction between streptomycin and the A-site causes structural changes to
the latter, which still allow it to bind tRNA but interfere with its ability to recognize and reject
incorrect pairs. This translational miscoding leads to the synthesis of faulty protein molecules,
which in turn causes cell damage.119, 160
Chlortetracycline interacts with the A-site as well; it blocks the binding of aminoacyl-tRNA
directly and stops the mRNA from being translated.71 Fusidic acid interferes with protein
synthesis by binding to and inhibiting the function of peptide elongation factor G (EF-G),
which promotes the translocation of tRNA from the A-site to the peptidyl or P-site.2, 28, 102
Mupirocin inhibits protein synthesis but does not bind to either the 50S or the 30S subunits.
It inhibits protein synthesis by limiting the supply of one specific aminoacyl-tRNA, namely,
isoleucyl-tRNA, to the ribosome. It binds to the active site of isoleucyl-tRNA synthetase as an
analogue of isoleucyladenylate, which stops the production of isoleucyl-RNA.40, 86, 187, 208, 220
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Figure 1.6 Structure and mechanism of action of puromycin. Puromycin (Pm) is structurally similar
to the aminoacyl moiety of aminoacyl-tRNA and is attached to the c-terminal of a growing peptide.
The presence of an amide bond (purple) instead of an ester bond terminates the synthesis of the
peptide and causes its premature release. With ribosomes engaged in the synthesis of membrane
proteins, the premature release of the peptide will leave the translocon pore stuck in an open state,
which will make the membrane leaky to small solutes.160
Puromycin is an analogue of the aminoacyl moiety in aminoacyl-tRNA, which is mistak-
enly picked up by the ribosome and added to the C-terminal of a growing peptide (Figure 1.6).
Instead of an ester bond that would yield to nucleophilic attack by the next incoming amino
acid, puromycin has an amide bond, which cannot participate in the subsequent elongation re-
action and leads to the termination of peptide synthesis.11, 149, 222 In addition to the direct harm
caused by the incomplete peptide synthesis, the premature release of the peptide from ribosome
can also lead to a secondary damage on membranes. When the protein undergoing synthesis is
an integral membrane or secretory protein, the ribosome will be attached to a translocon pore
that spans the cytoplasmic membrane (or in eukaryotes, the ER membrane). The nascent pro-
teins are guided to their destinations by these pores. Once the peptide is prematurely released,
the translocon pore is left open and becomes a pathways for small solutes to permeate across
the membrane freely.185, 186
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Figure 1.7 Inhibition of bacterial DNA and RNA biosynthesis. Rifampicin (rifamycin class), novo-
biocin (aminocoumarin class) and nalidixic acid (quinolone class) exert their activity by deactivating
enzymes. Metronidazole can break DNA strands directly.
1.2.4 Inhibition of DNA and RNA synthesis
Another group of drugs find their targets upstream of ribosomal protein synthesis, that is, in
DNA and RNA synthesis. They can either interrupt DNA and RNA replication or directly dam-
age DNA (Figure 1.7). Some representative drugs are rifampicin (rifamycin class), novobiocin
(aminocoumarin class), nalidixic acid (quinolone class), and metronidazole (nitroimidazole
class).
Bacterial DNA-dependent RNA polymerase comprises multiple subunits. Rifampicin binds
to the active site of the β -subunit, which catalyzes the polymerization. The binding strongly
inhibits DNA transcription and particularly the initiation stage.30, 70, 188, 214 The eukaryotic
enzymes are much less sensitive to inhibition by rifampicin.81 Novobiocin and nalidixic acid
both exert their antibacterial activity by inhibiting the function of bacterial DNA gyrase, a
type II topoisomerase (also see Section 1.3.1). Though neither novobiocin nor nalidixic acid
are clinically important these days, some of the newer generation drugs from their classes are
widely used, such as ciprofloxacin (a gyrase inhibitor from the quinolone class).
The unique and essential functions of enzyme topoisomerases make them excellent drug
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targets. The length of a cell’s DNA is much longer than that of the cell contains it. In order
to be accommodated inside the cell, these DNA strands are coiled and supercoiled to adopt
a much more compact form. This process requires topoisomerase. On the other hand, DNA
strands need to be relaxed and disentangled before replication or transcription, which again
requires topoisomerase.42, 180, 196, 197 Gyrase (type II topoisomerase) can cut both strands of
one DNA double helix and then re-ligate them after passing an intact double helix across the
gap. This relaxation of DNA coils grants access to DNA-associated enzymes.
Metronidazole acts selectively against anaerobic bacteria. After entering the cells, it is
reduced by the low-redox-potential enzyme pyruvate:ferredoxin oxidoreductase and ferredoxin
to a highly reactive nitro intermediate form. This unstable intermediate may attack and break
DNA strands.116 In addition to infections with anaerobic bacteria, nitroimidazoles are also
useful in treating infections caused by anaerobic eukaryotic pathogens, such as Trichomonas
vaginalis.58, 160
1.2.5 Inhibition of folate metabolism
The metabolism of folate plays an crucial role in many biochemical pathways (Figure 1.8).
It provides single carbon units for the biosynthesis of thymine (dTMP), purine bases, and the
amino acid methionine, which serve as basic building blocks in the synthesis of DNA, RNA,
and proteins. Methionine is also an important intermediate in the S-adenosylmethionine (SAM)
cycle that brings about a number of methylation reactions. The two well-known antibiotics that
inhibit folate metabolism are sulfonamides and trimethoprim.
In all of these folate-dependent pathways, tetrahydrofolate (THF) is the pivotal compound.
THF is reduced from dihydrofolate (DHF) by dihydrofolate reductase (DHFR). The synthetic
drug trimethoprim works as a DHFR inhibitor due to its structural resemblance of DHF (Fig-
ure 1.9). Even though DHFR is required in both bacteria and human folate metabolism, the
structural differences between the human and bacterial enzymes make trimethoprim selectively
toxic towards bacteria.
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Figure 1.8 Inhibition of bacterial folate metabolism. The participation of folate is crucial in multi-
ple biochemical pathways; some major compounds provided by these pathways are highlighted in
pink. The production of THF is in the center of these pathways, and hence is the target for antibi-
otics. Sulfonamide and trimethoprim inhibit activities of dihydropteroate synthase and dihydrofolate
reductase (DHFR) respectively.
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Figure 1.9 Structures of compounds that interfere bacterial folate metabolism. Sulfonamides and
trimethoprim share structural similarities with PABA and with DHF, respectively, and act as their
antimetabolites.
To obtain DHF, bacteria and humans utilize two completely different routes. Humans get
folic acid directly from a variety of dietary sources and then convert it to DHF via a NADPH-
dependent reduction reaction (also catalyzed by DHFR). On the other hand, bacteria have to
synthesize DHF themselves. Firstly, dihydropteroate is produced by incorporating the precur-
sor p-aminobenzoic acid (PABA) into a pteridine diphosphate, followed by the release of a
diphosphate group; this reaction is catalyzed by the enzyme dihydropteroate synthase. Subse-
quently, the dihydropteroate is further modified to produce DHF (Figure 1.8). Sulfonamides
and PABA have very similar structures and compete for enzyme substrate binding sites. This
competition can effectively inhibit the synthesis of folate and any subsequent reactions.
Sulfonamides and trimethoprim inhibit the same pathway in a successive steps. Their an-
tibacterial effects are synergistic, and they are thus often used in combination. However, the
prevalent resistance and the concern of allergic reactions to them have greatly limited the usage
of sulfonamides.
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1.2.6 Disruption of bacterial cell membranes
There are also some antibacterial agents that are not necessarily involved in enzyme function
or metabolic pathways but can kill bacteria by disrupting their cell membranes. However, most
of them are not selective towards bacterial cells and hence are too toxic for clinical application.
So far, two such drugs have been clinically approved, namely, polymyxin and daptomycin.
Polymyxin is a positively charged cyclic lipopeptide antibiotic with a short acyl side chain.
It binds to the outer membrane of Gram-negative bacteria, and more particularly to lipid A,
the hydrophobic anchor of lipopolysaccharide (LPS). Adjacent LPS molecules form a network
through hydrophobic forces and bridging cations (Ca++). This organized network is crucial
to maintain the cell wall’s integrity. The binding of polymyxin interrupts the hydrophobic
interaction and also displaces Ca++, which leads the destabilization and disruption of the outer
membrane.65, 160, 165, 172 The mechanism of action for daptomycin is explained in Section 1.4.3.
Valinomycin acts on cell membranes as a potassium ionophore. It has a cyclic peptide
structure which wraps tightly around a potassium ion and exposes a hydrophobic exterior. This
complex can easily diffuse through membranes and dissipate the potassium concentration gra-
dient, and thus cause the disruption of cell’s membrane potential. Valinomycin is not selective
for bacteria but also acts on mammalian cells. It thus is too toxic for medical use; however, its
high specificity for potassium ions makes it very useful for research in biochemistry and cell
biology, including some of the experiments described in the following chapters.
1.3 BACTERIAL RESISTANCE TO ANTIBIOTICS
The existence of bacterial resistance has been a concern since the beginning of the antibiotic
era. Mass production and a wide range of application of antibacterials in the past 70 years has
created a very strong selection pressure for bacteria and promoted the emergence and spreading
of resistance.
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To combat bacterial resistance, new drug classes were developed to attack different bacte-
rial targets. As mentioned above, a variety of targets have been exploited. Notwithstanding
the diversity of the antibacterials’ action mechanisms and targets, the resistance mechanisms
employed by bacteria toward them can be broadly divided into three categories: (1) modifica-
tion of drug targets, (2) enzymatic drug inactivation, and (3) enhanced efflux and/or reduced
uptake of drugs. Most drugs encounter more than one resistance mechanism in different bac-
terial species or strains. Even individual bacterial strains may employ multiple mechanisms of
resistance toward a specific single drug. A summary of the resistance mechanisms is given in
Table 1.1.
1.3.1 Target modification
Target modification is the most common way to confer resistance to bacteria, and almost all
antibiotics encounter this problem. Many drug classes that were previously mentioned directly
target and inhibit enzymes that have essential functions in the life of the bacterial cell. To
counter this inhibition, the targeted enzymes may acquire mutations that abolish or reduce
the affinity for the inhibitory drug, sometimes even at a cost to their own fitness.109 One of
many examples is rifampicin resistance. Rifampicin, which is an important drug in the treat-
ment of tuberculosis, targets β -subunit of bacterial RNA polymerase that is encoded by rpoB.
Resistance-conferring mutations in rpoB may take the shape of point mutations, deletions, and
insertions.74, 123 Collectively, they occur with unusually high frequency, which may lead to
rapid selection of resistant strains under therapy. Rifampicin should therefore never be used
for monotherapy but in combination with one or more other antibiotics (see Section1.3.6).
Mutations that render a target enzyme resistant to its cognate antibiotic can in principle arise
spontaneously in any bacterial strain. Alternatively, a bacterium can also acquire resistance
through the wholesale adoption of a foreign gene that encodes a homologous enzyme which is
naturally resistant to the drug. This is the case with methicillin-resistant Staphylococcus aureus
(MRSA), which have acquired a transpeptidase enzyme from other staphylococcal species.
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Table 1.1 Mechanisms of bacterial resistance to antibiotics.
Antibiotic (Class) Target Resistance mechanism
Inhibitors of murein synthesis
Fosfomycin (epoxide) Enzyme MurA Destruction by ring-opening epoxidases;
mutational inactivation of the glycerophosphate
transporter
Cycloserine Alanine racemase and
D-alanine ligase
Mutations in target enzymes
Moenomycin Transglycosylase Not fully understood
Bacitracin Undecaprenol
pyrophosphate (UPP)
overexpression of competing UPP phosphatase
Vancomycin
(glycopeptide)
D-Ala-D-Ala on lipid II
pentapeptide
Replacement of D-Ala-D-Ala with D-Ala-D-Lac
Penicillins,
cephalosporins,
carbapenems,
monobactams
β -lactam antibiotics
target transpeptidases
that cross-link
peptidoglycan chains in
the bacterial cell wall
Most commonly through deactivation by
β -lactamase; MRSA express enzyme with low
antibiotic binding affinity; mutation of porins
Inhibitor of mycolic acid synthesis
Isoniazid Activated by KatG;
adduct inhibits InhA
Expression of impaired KatG; mutations on
InhA
Inhibitors of ribosomal protein synthesis
Fusidic acid (steroid) Peptide elongation
factor G (EF-G)
Mutations in EF-G
Streptomycin
(aminoglycoside)
Ribosomal A-site
(protein S12, 16S
rRNA)
Mutations on S12 and 16S RNA; modification
by aminoglycoside acetyltransferases,
phosphotransferases, and
nucleotidyltransferases; efflux
Chlortetracycline
(tetracycline)
16S rRNA Efflux; expression of tetracycline binding
proteins; oxidation by TetX
Puromycin Antimetabolite of
aminoacyl-tRNA
Modified by puromycin acetyltransferase
Mupirocin Isoleucyl-tRNA
synthetase
Expression of resistant enzyme
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Antibiotic (Class) Target Resistance Mechanism
Oxazolidinones 23S rRNA Mutations of 23S rRNA
Chloramphenicol 23S rRNA Modified by chloramphenicol
acetyltransferases; mutation of porins
Pleuromutilin 23S rRNA Mutation of 23S rRNA
Erythromycin
(macrolide)
23S rRNA Methylation and mutation of 23S rRNA;
modification by by macrolide esterases or
phosphotransferases; efflux
Lincomycin
(lincosamide)
23S rRNA Methylation and mutation of 23S rRNA;
lincosamide nucleotidyltransferases
Streptogramin 23S rRNA Methylation and mutation of 23S rRNA;
streptogramin acetyltransferases
Inhibitors of DNA and RNA synthesis
Novobiocin
(aminocoumarin)
DNA gyrase Mutation of DNA gyrase; efflux
Nalidixic Acid
(quinolone)
DNA gyrase Efflux; mutation of porins; mutation of DNA
gyrase
Rifampicin RNA polymerase Mutation of RNA polymerase;
ADP-ribosylation of drug; efflux
Metronidazole
(Nitroimidazole)
DNA strands Reduced drug activation; efflux
Inhibitors of folate metabolism
Sulfonamide Dihydropteroate
synthase (DHPS)
Mutation of DHPS
Trimethoprim Dihydrofolate reductase
(DHFR)
Mutation or overexpression of DHFR; certain
pathogens don’t have DHFR and use alternative
cofactors for carbon transfer
Cell membrane disruption
Polymyxin B Lipid A core of
lipopolysaccharide
(LPS)
Modifications on LPS
Daptomycin
(lipopeptide)
Phosphatidylglycerol in
cytoplasmic membrane
Changes in membrane lipid composition
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Target modification applies not only to protein enzymes but also to ribosomes, and more
specifically to the ribosomal RNA. As mentioned above in Section1.2.3, the MLS group an-
tibiotics share a common binding region on the 23S rRNA of the 50S subunit. Resistance
to these antibiotics can arise through the methylation or dimethylation of a specific adenine
residue, equivalent to E. coli coordinate 2058 (A-2058), which causes a structural change to
the 23S RNA that denies drug binding. This methylation is catalyzed by adenine-specific N-
methyltransferases which are encoded by the erm (erythromycin ribosome methylation) class
of genes. The erm genes are found in a wide range of bacterial species, including the antibi-
otic-producing Streptomyces species and many pathogens. Due to the similarity between their
binding sites, cross-resistance among MLS group drugs is fairly common.112, 167, 215
1.3.2 Target overexpression
In addition to modifying targets, some bacterial strains gain resistance to antibiotics by overex-
pressing the corresponding drug targets. In a favorable scenario of treating bacterial infections,
the activity of the target is effectively inhibited to a level at which the bacteria can not long
survive. Even though the molar concentration of an antibiotic is normally far higher than that
of its target, the antibiotic will only inhibit its target to a certain extent but not completely.
Assuming a reversible interaction, the residual active fraction of the target will remain constant
as long as the antibiotic concentration does, too. Therefore, when target expression increases,
the absolute amount of uninhibited target will increase proportionally. Once the amount of
uninhibited target reaches a sufficient level of activity, the bacterial strain will have achieved
resistance to the drug.
The overexpression of target would appear to be a straightforward way for bacteria to de-
velop resistance; however, this does not hold true for all drugs. An instructive example of
divergent effects of target overexpression is provided by the comparison of sulfonamides and
trimethoprim. As discussed in Section 1.2.5, both are inhibitors of folate metabolism, with
dihydropteroate synthase (DHPS) and DHFR as the respective targets (Figure 1.8). Both drugs
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are challenged by widespread resistance. With trimethoprim, target overexpression works as
expected, and it is indeed one of the major resistance mechanisms encountered in resistant
strains. In contrast, resistance to sulfonamides due to overexpression of DHPS has not been
observed in any resistant isolates, and when induced experimentally in laboratory strains, no
change in susceptibility towards sulfonamide occurs.157 Nevertheless, a much earlier study
showed that resistance is conferred by an increase of PABA, the regular substrate of DHPS, as
would be expected with competitive inhibition.111
The apparent contradiction in these finding can be resolved by considering the subtleties of
the action mechanism of sulfonamides.157 Sulfonamides compete against PABA for binding to
DHPS, but they do not inhibit the catalytic activity of DHPS. Instead, they become substrates
themselves and undergo coupling with pteridine diphosphate, and the depletion of this precur-
sor is responsible for the inhibition of folate metabolism by sulfonamides. The overexpression
of DHPS will not change the proportion of correct and aberrant product formed, and thus will
not affect the level of bacterial susceptibility.
Another interesting example is DNA gyrase, the target for the two antibiotics coumermycin
A1 and ciprofloxacin, which belong to the aminocoumarin and the quinolone class, respectively
(Figure 1.7). When susceptible E. coli strains were modified to overexpress DNA gyrase, they
became resistant to coumermycin A1 but more susceptible to ciprofloxacin. These opposite
effects are due to the two drugs’ different mechanisms of action. Coumermycin A1 competes
against ATP for binding, which inhibits DNA gyrase; this inhibition can be compensated by
overexpression. On the other hand, ciprofloxacin inhibits gyrase only partially; it still permits
the DNA cleavage by gyrase but prevents DNA re-ligation. The drug-bound gyrase will there-
fore induce an accumulation of DNA double-strand breaks. Therefore, ciprofloxacin changes
the enzyme’s activity from useful to toxic, and overexpression of gyrase would only make the
host bacteria more susceptible to the drug.
These findings show that the effect on drug susceptibility conferred by target overexpres-
sion is dictated by the specific mechanism involved in the drug-target interaction. If the drug
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strictly inhibits the target activity, overexpression of the target will result in drug resistance; in
contrast, if the drug alters the target’s activity, overexpression may not induce resistance, and
may even enhance the drug’s toxicity. In some cases, target overexpression may exert a heavy
fitness cost to the bacterium. An example are the penicillin-binding proteins (PBPs) 1A, 1B,
and 2. The overexpression of these proteins can significantly reduce the growth rates of their
host E. coli strain,157 and in case of PBP2 can even result in cell lysis.114
1.3.3 Drug inactivation
Instead of taking a passive approach to adapt, bacteria may also develop resistance by directly
modifying and thereby inactivating drug molecules. The most common types of modifications
are hydrolysis and group transfer, which are carried out by a variety of enzymes.218
Many antibiotics have ester and amide bonds that are essential to their activity. But these
bonds are also very susceptible to hydrolysis. The widespread resistance to β -lactam antibi-
otics due to β -lactamases is the best known and most important example. There are two major
types of β -lactamases, namely, the serine enzymes and the metallo-enzymes. Inhibitors that
can be used to protect the antibiotics are only available for the former, not the latter (Figure
1.10).
As briefly mentioned earlier, the β -lactam antibiotics exert their activity by forming stable
covalent derivatives with the target enzyme transpeptidase, which opens the β -lactam ring and
inactivates both the antibiotic and its target enzyme completely. Ring opening and formation
of a covalent bond between drug and enzyme are mediated by a serine residue in the active site
(Figure 1.10, middle). Serine β -lactamases can open the β -lactam ring and form a covalent
bond in the same way via a catalytic serine residue (Figure 1.10, left), which inactivates the
drug. The covalent intermediate is then readily hydrolyzed, which releases and reactivates the
β -lactamase molecule.
Clavulanic acid by itself is a very weak β -lactam antibiotic; however, its unique interaction
with serine β -lactamase makes it clinically useful (Figure 1.10, right). This interaction involves
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Figure 1.10 Action mechanisms of serine β -lactamases and of clavulanic acid. In the absence of
β -lactamase, the catalytic serine residue of transpeptidase attacks the β -lactam ring of penicillin to
form a stable and inactive derivative (middle). The same reaction is also carried out by β -lactamase
(left); however, this enzyme releases itself through hydrolysis, which yields an inactivated penicillin.
Clavulanic acid (right) can react with β -lactamase as well, but it engages two serine residues in
the active site. The bond formed via the second serine residue is stable and hence inactivates the
enzyme.
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two serine residues in the active site. The covalent bond formed with the first serine residue is
still easily hydrolyzed, but before this happens, the reactive intermediate forms a stable bond
with the second serine residue, which leaves it attached to the β -lactamase molecule even after
the first bond is cleaved. This unique feature makes clavulanic acid an effective serine β -
lactamase inhibitor. Hence, it is successfully used in combination with β -lactam antibiotics
like amoxicillin to overcome resistance.160
The hydrolysis catalyzed by a metallo-β -lactamase (MBL) is achieved by activation of
water via a Zn++ active center, which does not involve a serine residue and makes it immune
to inhibitors like clavulanic acid. There has not been much success in finding inhibitor for
MBLs until very recent. In the study done by Wright and colleges,100 it was shown that a
fungal natural product, aspergillomarasmine A (AMA), can function as a rapid and potent
inhibitor to certain clinically important MBLs, such as NDM-1 and VIM-2. When AMA was
used in combination with meropenem, a carbapenem antibiotic, the activity of meropenem was
efficiently restored against bacteria strains possessing either NDM or VIM-type alleles.
Most of the enzymes that inactivate antibacterials are group transferases. These enzymes
covalently link drugs with groups such as acyl, phosphoryl, thiol, and glycosyl moieties. The
addition of functional group will cause structural changes and impair target binding. Example
group transferases are chloramphenicol acetyltransferases and aminoglycoside kinases.
The activity of prodrugs like metronidazole and isoniazid, which were mentioned earlier,
relies on activation by bacterial enzymes. Resistance may occur when bacterial strains down-
regulate the expression of those enzymes, so that most of the drug molecules remain in their
inactive prodrug forms.56, 204, 209, 225
1.3.4 Efflux and reduction of uptake
Another strategy for bacteria to to lower the intracellular drug concentration is by reducing
uptake and/or inducing efflux of drugs.104 To get across a Gram-negative bacterial cell, a drug
molecule needs to traverse the outer membrane, either by diffusion across the lipid bilayer or
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Figure 1.11 Schematic representation of efflux pumps that confer bacteria drug resistance. Single-
component pumps span only one membrane, across which the target molecules are transported
from the bacterial cytoplasm to the outside for Gram-positive bacteria, or to the periplasmic space
for Gram-negative ones. RND type pumps span both membranes (inner and outer) and the
periplasmic space. They capture the target molecules from the periplasmic space (not the cy-
toplasm) and extrude them to the outside.
through porin channels. The outer leaflet of the outer membrane is composed of lipopolysac-
charide (LPS), which is impermeable to many compounds. Therefore, many drugs, such as
β -lactams, chloramphenicol, and fluoroquinolones, have to go through porin channels. Certain
bacteria have gained resistance by reducing porin expression or altering the size and selectivity
of porin.34, 47, 80, 206
For the drugs that have successfully crossed the cell wall, bacteria may use efflux pumps
to send them back out again. In susceptible bacterial strains, there is either no or very weak
drug efflux. To develop resistance, bacteria start to enhance the efflux by overexpressing ef-
flux pumps or acquiring more efficient pumps through gene transfer. Some of these pumps are
simple single-component transporters, while others are multi-component systems, such as the
resistance-nodulation-cell division (RND) transporters found in Gram-negative bacteria (Fig-
ure 1.11). Some of these transporters have low substrate selectivity, which enable them to
efflux multiple distinct types of drugs and make their host bacteria multidrug-resistant. This
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multidrug resistance mechanism is not only a great challenge to the current antibacterials, but
also a burden for future drug development.104, 160
The single-component pumps span a single cell membrane. Gram-positive bacterial cells
have a relatively simple envelope structure, with only a cytoplasmic membrane; therefore,
single-component efflux transporters are sufficient to pump the target molecules back to the
outside in this case. In contrast, Gram-negative bacterial cells have an inner and an outer
membrane. Even though they also have simple single-component pumps, by which resistance
to certain drugs is conferred, the most prominent ones are the multi-component RND trans-
porters.
These tripartite RND transporters cross both the inner and the outer membrane and can
efflux a wide range of antibiotics (Figure 1.11). So, are they just like the single-component
pumps but with longer wingspans that can pick up the targets from the cytoplasm and send
them right across two membranes to the outside? Not really, as a number of studies have
shown that they have a much more intriguing and intricate mechanism, and they are capable of
promoting a very strong drug resistance.
In a study done by Lomovskaya and colleagues,113 several combinations of efflux pumps
(with overlapping drug specificity) were expressed in the same bacteria strains, and then the
magnitude of resistance conferred by them was evaluated. Two different patterns of resistance
enhancement were observed. When two pumps of the same type were combined, either sin-
gle-component or RND, the resulting degree of resistance was additive. In contrast, when the
combination consisted of one single-component and one RND pump, a multiplicative enhance-
ment of drug resistance was conferred.
The authors explained the observations by a model based on the concentration gradients
generated by efflux pumps. When two types of pumps were involved, two concentration gra-
dients (crossing both inner and outer membrane) would be created, whereas the single type
pumps could only create one of the gradients. However, they did not address the location
where the drug molecules would be captured by the RND pumps.
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In a later theoretical study by Palmer,159 it was shown that, in order to achieve the observed
multiplicative enhancement of drug resistance, RND pumps must be capable of capturing the
drug molecules from the periplasmic space. Many functional62, 122, 203and structural57, 118, 146
studies also supported this model.
The best-studied RND pumps are AcrAB-TolC from E. coli, and MexAB-OprM from Pseu-
domonas aeruginosa. These RND pumps comprise an inner membrane spanning pump (AcrB,
MexB), an outer membrane pore (TolC, OprM), and a periplasmic protein (ArcA, MexA) that
aligns and surrounds the first two. Some very thorough studies done on AcrAB-TolC have
revealed a very detailed working mechanism of this type of pump.145, 175 AcrB exists as a
trimer and extracts drug molecules from the periplasmic space only. The trimer-drug complex,
driven by the proton-motive force across the inner membrane, rotates around the axis that goes
through the center of the TolC pore. During the rotation, the three subunits are cycling through
three different conformations, which correspond to three functional steps. The first step grants
the substrate access to the binding pocket from the periplasm. The second step expands the
binding pocket to accommodate the substrate. In the final step, the entry pathway is closed off,
and the the substrate is extruded through the TolC pore to the outside.
1.3.5 Origin and spread of resistance
Some of the resistant strains are the result of spontaneous mutations. Due to the large pop-
ulation and short reproductive cycles of bacteria, mutations that will enable a given strain to
endure higher levels of some specific antibiotic tend to arise frequently, and such mutants are
observed readily in the presence of the drug. Using serial passage with stepwise increases of
the drug concentration, highly resistant strains can often be readily selected in vitro.
While this mechanism is straightforward and indeed accounts for the development of re-
sistance toward single antibiotics under therapy, the limitations of its explanatory power were
noticed early on. In the 1950s, streptomycin, tetracycline, and chloramphenicol were intro-
duced and widely used as alternatives for sulfonamides in the treatment of Shigella dysentery.
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While resistance was observed initially only to individual agents, several years later clinical
isolates were obtained that had acquired resistance to all four drugs simultaneously, often in-
cluding ones that had not been used on the patient in question.189
It was conceptually very difficult to explain the observation by mutation and selection. Mu-
tations that mediate resistance to a single drug arise with a frequency of about 10−7 to 10−10
per bacterium and generation; therefore, the probability of achieving resistance to four distinct
antibiotics simultaneously is exceedingly low. It was then also observed that the multidrug
resistance trait could readily be transferred between bacterial cells. The phenomenon of trans-
ferable resistance gave rise to extensive studies and fascinating discoveries, many of which
have greatly advanced the development of molecular biology.
As we know today, a large number of bacteria acquire their resistance from others through
horizontal gene transfer. This transfer can bridge species barriers and involve both pathogenic
and non-pathogenic strains. In many cases, the resistance genes being transferred can be traced
back either to the antibiotic producing organisms, which need them to avoid committing suicide
while producing antibiotics, or to non-producing strains, which rely on them to survive in
the vicinity of the former. Most antibiotics are produced by soil microorganisms. The most
abundant class of soil bacteria are actinomycetes; therefore, it is not a surprise that many
actinomycetes are naturally resistant to multiple antibiotics.45
The horizontal propagation of antibiotic resistance genes is mediated by three key genetic
vehicles: conjugative plasmids, transposons, and integrons.155
Plasmids are extra-chromosomal, independently replicating, double-stranded circular DNA
molecules. They are the major vehicle for the exchange of genetic material between bacterial
cells. A particularly efficient form of plasmid transfer is known as conjugation (Figure 1.12).
The plasmids involved in this process are conjugative plasmids, similar to the prototypical F-
plasmid (“F” stands for fertility). The F-plasmid enables its host cell (donor cell) to produce
pili and initiate conjugation. During the conjugation, one strand of the F-plamsid is released
and transferred to recipient cell. Inside the latter, the complementary strand is synthesized,
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Figure 1.12 Schematic representation of gene transfer by bacterial conjugation. The donor cell
contains an F-plasmid, which can initiate conjugation by expressing a pilus. The donor pilus
reaches to the recipient cell and creates a bridge between both cells (1). The pilus then retracts
and brings the two cells into close contact to form a channel, through which one strand of the F-
plasmid is transferred to the recipient cell (2). Finally, the single-stranded plasmids in both donor
and recipient cells are replicated to form complete double-stranded plasmids, and the conjugation
completes (3).
which provides the recipient cell with an identical copy of the double-stranded F-plasmid. If
antibiotic resistance genes are carried by these conjugative plasmids, which are then referred to
as R-plasmids or R-factors, these resistance traits can be easily spread among bacterial species.
Transposons are also mobile DNA molecules. They differ from plasmids by being smaller,
linear, and incapable of traveling between cells just by themselves. However, transposons are
very active travelers within the cell; they can jump from plasmid to plasmid, from plasmid
to chromosome, and from chromosome to plasmid. Therefore, in order to cross the cell the
membrane barriers, transposons need to jump aboard conjugative plasmids.
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Figure 1.13 Schematic representation of transposons. Insertion sequence (IS) is the basic trans-
posable element (top). A resistance gene can be incorporated into either a simple transposon
(middle) or a complex transposon (bottom).
The basic transposable elements found on transposons are also referred to as insertion se-
quences (ISs). Each insertion sequence has a transposase gene plus a pair of inverted repeats
(IRs) flanking it (Figure 1.13). When extra structural genes (such as antibiotic resistance genes)
are associated with the ISs and become movable, the whole construct is called a transposon,
which is denoted by “Tn” and a number.
In a direct transposition, or so-called “cut and paste” transposition, the transposase rec-
ognizes the terminal IR sequences and cuts at each end to excise the whole transposon from
the donor DNA. The transposase also introduces a staggered cut into the recipient DNA, into
which the cut-out transposon is then inserted.
In a simple transposon, only one IS element is involved. Using Tn3 as an example here
(Figure 1.13, middle), the extra genes (coding for resolvase and β -lactamase) and transposase
gene are located between one pair of IRs.76, 83 Different from direct transposition, Tn3 uses
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Figure 1.14 Schematic representation of Tn3 replicative transposition. Both the donor and the re-
cipient DNA are first nicked by transposase. The donor and recipient DNA molecules are then linked
covalently at their openings (1). The ensuing single-stranded gaps are filled by replication, which
produces a DNA molecule with two copies of the transposon, also called a cointegrate(2). The
cointegrate is resolved by resolvase through site-specific recombination between the two transpo-
son copies, which restores the original donor DNA and also creates a transposon-carrying recipient
DNA (3). The cutting sites are indicated by arrows.
a replicative transposition mechanism, which includes a replication of the transposon, so that
a copy of it is left at its original site. In the model proposed by Shapiro (Figure 1.14),179 the
transposase first cuts the donor DNA to expose the 3’-OH groups at the ends of transposon
Tn3 and also makes a staggered cut in the recipient DNA. Then the donor and recipient DNA
molecules become covalently linked, with the gaps being filled by DNA replication. The result
is a DNA molecule that has two copies of the transposon, which is called a cointegrate. The
transposon-encoded resolvase finally resolves the cointegrate through site-specific recombina-
tion within the transposon, which release the donor DNA in its original form and the recipient
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Figure 1.15 Schematic representation of an integron. Integrons consist of an attachment site (att),
a gene (intl) encoding the integrase, and a promoter that drives the expression of incorporated
genes. The incorporated genes are obtained from gene cassettes. The site-specific recombination
events rely on the recognition of 59-base elements.155
DNA with a new copy of the transposon.
In a complex (composite) transposon, the structural genes are flanked by two copies of an
IS (Figure 1.13 bottom). Examples are transposons Tn5 and Tn10,155 which contain genes that
confer resistance to streptomycin and to tetracycline, respectively.
Integrons are gene expression platforms that incorporate promoter-less genes and convert
them into functional genes. An integron consists of three elements (Figure 1.15): (1) an at-
tachment site where the acquired sequence is integrated; (2) a gene encoding integrase, a
site-specific recombinase; and (3) a promoter that drives the expression of the incorporated
sequences. Integrons incorporate genes from gene cassettes, which are small circular DNA
molecules that often carry antibiotic resistance genes. These gene cassettes also contain a re-
combination site known as a 59-base element even though it might not be exactly 59 bases
long. The integrase can recognize different 59-base elements, allowing the incorporation of
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multiple resistance genes within a single integron.
In contrast to plasmids and transposons, integrons are not mobile all by themselves. In order
to unleash their potential in spreading resistance, integrons need to be incorporated into either
a plasmid or a transposon first, and in most cases, integrons are found within transposons.
An example of multi-drug resistance spreading via integrons is the Shigella dysentery case
mentioned at the beginning of this section (1.3.5).127, 155
1.3.6 Antibacterial combination therapy
Combinations of two or more antibiotics are widely used in the treatment of bacterial infec-
tions. In some cases, this approach is used because of practical limitations. For example, in
severely ill patients, it is necessary to begin treatment immediately, before the pathogen can be
identified and its drug susceptibility profile can be determined. At this initial stage, antibiotics
will have to be selected empirically in order to cover an appropriately broad spectrum of patho-
gens and resistance patterns. This situation is typical of complicated infections such as sepsis
and meningitis.24, 161
In many cases, combination therapy is still preferred after the complete information on
the pathogen is available. Carefully selected combinations can produce synergistic effects,
which means that the antibacterial activity is greater than the sum of the effects of the indi-
vidual agents. Such synergistic action may result in greater or more rapid therapeutic success.
Examples include the treatment of Staphylococcus aureus and Enterococcus infections with
aminoglycosides and β -lactams (vancomycin). Combination therapy may also overcome re-
sistance to some important antibiotics from resistance; see for example the combination of
penicillin and clavulanic acid mentioned earlier (Section 1.3.3).
Another reason for combination therapy is the serious resistance issue. The most well-
known example is the treatment for tuberculosis. Tuberculosis is caused by Mycobacterium
tuberculosis, which has very unique cell wall structure and growth properties.75 These features
allow the bacteria to survive under therapy for several months, and the treatment accordingly
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takes a long time. If monotherapy was used, the risk of mutations that induce resistance would
be unacceptably high. A more recent study also found that within a clonal population of my-
cobacteria, the cells showed unusually asymmetric division and growth, which generated many
distinct sub-populations of cells. These physiologically distinct cells also showed different
susceptibility profiles to the important drugs.4 Combination therapy with three or four drugs
greatly reduces the risk of emergent resistance. The standard combination used today includes
the four drugs rifampicin, isoniazid, pyrazinamide, and ethambutol.
1.4 DAPTOMYCIN
Daptomycin (Cubicinr), the subject of this thesis, is the first lipopeptide antibiotic approved
for clinical use. Since its approval in 2003, daptomycin has become one of the most effective
and widely used antibiotics for treating serious infections caused by Gram-positive bacteria,
including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant En-
terococcus (VRE) strains.9, 32, 199
Daptomycin is produced by Streptomyces roseosporus, a soil actinomycete first isolated by
researchers from Eli Lilly and Company in the early 1980s.49, 60, 61 Under normal conditions,
daptomycin is produced along with other structurally similar lipopeptides that all share an
identical core cyclic peptide structure but bear different lipid tails. Collectively, they are called
the A21978C lipopeptides.14
The A21978C core cyclic peptide comprises 13 amino acids (Figure 1.16), including a
number of non-proteinogenic and D-amino acids, namely, ornithine, kynurenine, 3-methylglu-
tamic acid, D-alanine, D-serine, and D-asparagine. The amino acid residues Asp-7 and Asp-9
were shown to be essential for antibacterial activity.77 Ten of the amino acids cyclize to form a
ring closed by an ester bond between the side chain hydroxyl group of Thr-4 and the C-terminal
kynurenine (Kyn-13). The fatty acyl tail is attached to the N-terminal Trp-1 on the exocyclic
peptide, which comprises the residual three amino acids. Unlike the structurally related antibi-
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Figure 1.16 Structures of daptomycin and amphomycin. Non-standard amino acids are ornithine
(Orn), kynurenine (Kyn), 3-methylglutamic acid (MeGlu), pipecolic acid (Pip), diaminobutyric acid
(Dab), and β -methylaspartic acid (MeAsp).
otic amphomycin, the peptide ring is closed by an ester bond instead of an amide bond; the
members of the A21978C group are therefore classified as cyclic depsipeptides.
While the clinical resistance to daptomycin is still very rare, sporadic case reports have still
drawn a lot of attention, since daptomycin has become a drug of choice for many life-threat-
ening infections. These observations have stimulated interest in developing novel daptomycin
derivatives with improved activity and a broader action spectrum. Such development efforts
would greatly benefit from an improved understanding of daptomycin’s mode of action.
In the rest of this section, I will first give a brief review on how daptomycin was developed,
and also on the previous progress in determining the action mode of daptomycin. At the end
of this section, I will talk about the progress in daptomycin resistance research.
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1.4.1 Preclinical development
The screening process is critical during drug development. It selects the candidates from a
compound library for further evaluation. A large library can not only increase the chances
of finding the candidates, but also provide a lot of information on possible further improve-
ments. Here, I will focus on the major approaches that have been used for the construction of
compound libraries for daptomycin analogues.
1.4.1.1 Semi-synthetic modification. It was observed early on that small changes to the acyl
tail could give significantly different toxicity profiles within the A21978C group. Accordingly,
screening a library of A21978C analogues having different lipid tails would be a logical ap-
proach to find new drugs.48 However, purification of individual A21978C analogues from the
fermentation mixture produced by S. roseosporus proved too laborious. Instead, a semi-syn-
thetic method was developed to generate such a library.
The basic idea is to obtain the A21978C peptide core through deacylation of the whole
naturally produced compound mixture. The peptide core can then be reacylated with different
natural or synthetic acyl tails. The deacylation is catalyzed by a deacylase enzyme produced
by Actinoplanes utahensis NRRL12052.22 However, if we go to the deacylation step directly,
the A21978C core will have two free amino groups (Trp-1 and Orn-6) available for subse-
quent acylation. To circumvent this complication, the Orn group was protected by mono-
tert-butyloxycarbonyl (tBOC) prior to deacylation. The monoacyl tails were reacted with the
N-terminal of Trp-1 as activated fatty acyl esters. The tBOC group was then removed by triflu-
oroacetic acid (TFA). By screening the library generated by this method, the derivative with an
n-decanoyl tail showed the best balance of antibacterial efficacy and low toxicity in animals,
and it was chosen for further clinical development and became the drug known as daptomycin
today.
While this semi-synthetic modification approach is good for making daptomycin analogues
on an experimental scale, it is not ideal for producing the quantities required for clinical appli-
cation. This difficulty was overcome through the addition of decanoic acid to the fermentation
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broth. This yields daptomycin as the major product, which can then be obtained in homoge-
neous form through further purification.90
In addition to the acyl tail modification, many other semi-synthetic modifications were also
performed to expand the analogue library. These modifications include substitutions of the
exocyclic amino acid residues132 and derivatizations of the Orn-6 side chain.84
1.4.1.2 Combinatorial biosynthesis. The analogues produced by semi-synthesis can only
represent limited structural diversity due to the lack of changes in the cyclic amino acid core.
To overcome this limitation, an approach of combinatorial biosynthesis was used, which is
based on the knowledge about the biosynthetic mechanism of A21978C (daptomycin), as well
as of the related lipopeptide antibiotics A54145 and calcium-dependent antibiotic (CDA).
Daptomycin is synthesized by a non-ribosomal machinery within S. roseosporus, which
relies on multiple enzymes at different stages (Figure 1.17).141, 166 The assembly of the pep-
tide core is carried out by three non-ribosomal peptide synthetases (NRPSs), DptA, DptBC,
and DptD.13, 14, 132 Each of these synthetases comprises multiple modules (Figure 1.17C). All
modules have a basic C-A-T domain structure, where domain C is for condensation, domain
A is for activation (or adenylylation), and domain T is for thiolation. The ATP-dependent acti-
vation occurs first. The activated L amino acid then forms a thioester with the T domain. The
C domain finally reacts the aminoacyl residue with the C-terminus of the peptide located on
the preceding T domain. In the process, the elongated peptide is transferred to the current T
domain.
Three of the modules have an additional E domain, which is an epimerase that catalyzes
the conversion of an L-amino acid to its corresponding D-isomer. Therefore, the amino acids
are always acquired from solution as their L forms and are converted to the D forms after
activation. This concerns residues D-Asn-2, D-Ala-8, and D-Ser-11. The synthesis of MeGlu-
12 is assisted by DptI, an α-ketoglutarate methyltransferase.120 The terminal module in DptD
contains a thioesterase (Te) domain, which catalyzes the formation of an ester bond between
Kyn-13 and Thr-4 to cyclize and release the completed lipopeptide.
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Figure 1.17 Biosynthesis of daptomycin by the Dpt non-ribosomal machinery. The incorporation of
each amino acid is facilitated by a specific module that contains a C-A-T domain structure and an
optional E domain, which mediate condensation, activation, thiolation, and epimerization, respec-
tively. A: ATP-dependent activation and thiolation by the A and T domain of the cognate module.
B: The C domain attaches its cognate amino acid to C-terminus of the peptide that is linked to
preceding T domain. C: The synthesis of the peptide core is carried out in sequence by three large
enzymes (DptA, DptBC, and DptD). Each of these enzymes contains multiple amino acid-confer-
ring modules. The DptF module supplies activated acyl tails to DptA. The thioesterase domain (Te)
at the end of DapD cyclizes and releases the lipopeptide. This figure is adopted from Dr. Muraih’s
thesis.141
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DptE, an acyl-CoA ligase, and DptF, an acyl carrier, are required to initiate the condensa-
tion, respectively activating and delivering the fatty acid moiety (decanoic acid for daptomycin)
to the N-terminus of Trp-1.217 After the fatty acid has been attached, the condensation begins
by release of Trp-1 and simultaneous elongation at its C-terminus with the following amino
acid (Figure 1.17B). Then the peptide continues to grow in the same fashion. The overall
condensation proceeds in the sequence of DptA, DptBC, and DptD.
Like A21978, both A54145 and calcium-dependent antibiotic (CDA) are lipodepsipep-
tides. A54145 is produced by Streptomyces fradiae23 and CDA by Streptomyces coelicolor
A(3)2.106 They share many structural similarities with A21978C antibiotics: they all contain
10-membered cyclic peptides; the fatty acyl tails are attached to the N-terminal of their exo-
cyclic residues (both of A21978C and A54145 have three exocyclic residues, while CDA has
only one), and they all have a putative calcium-binding DXDG motif at the same position.
They are also naturally produced by similar non-ribosomal systems as shown in Figure 1.18.
The A54145 synthetase system comprises four NRPS subunits (LptA, LptB, LptC, and LptD),
while CDA had three NRPS subunits (CdaPS1, CdaPS2, and CdaPS3). All of these NRPS
subunits are constructed in the same module-domain architecture. Therefore, through the use
of recombinant DNA techniques, novel synthetases can be assembled that combine different
portions of the three natural systems. In the construction of such recombinant synthetases,
three different approaches are plausible: (1) whole subunit substitution; (2) substitution of a
module or domain within a specific subunit; and (3) disruption of genes involved in amino acid
modification.
The NRPS subunits are encoded by overlapping genes in gene clusters, such as daptomy-
cin’s dpt gene cluster (Figure 1.18). It has been shown that sequential translation of these genes
from one transcript is not essential for robust daptomycin production. When one or more of the
dptA, dptBC, or dptD genes were deleted from the gene cluster, daptomycin production could
be restored by introduction of the expression plasmids containing the missing genes. To fa-
cilitate genetic manipulation and combinatorial biosynthesis, three dpt genes were engineered
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Trp   D-Glu   hAsn    Thr     Sar            Ala     Asp            D-Lys MeOAsp  Gly  D-Asn     MeGlu  Ile/Val
1       2       3       4        5             6       7                8         9        10    11          12      13
1       2       3       4        5             6       7         8       9      10       11          12      13
 1       2       3       4        5        6              7         8       9           10       11
Trp   D-Asn  Asp     Thr     Gly           Orn     Asp    D-Ala   Asp    Gly     D-Ser        MeGlu  Kyn
Ser     Thr     D-Trp   Asp     Asp   D-HPG       Asp     Gly    D-hAsn      MeGlu  Trp
lptA                           lptB                        lptC                       lptD
A54145
CDA
cdaPS1                              cdaPS2             cdaPS3
dptA                                         dptBC                          dptD            dptI
A21978C (Daptomycin)
D-Ser
D-Asn
D-Lys
D-Ala
D-Asn
D-Asn
Figure 1.18 Combinatorial biosynthesis of daptomycin analogues. The four major combinato-
rial factors are: whole NRPS subunit substitutions (dashed box), modual or domain substitutions
(dashed arrows), disruption of dptI gene (dashed oval), and lipid tail variations.
to express from different chromosomal loci under the control of separate promoters (ermEp∗
promoters were used for dptA and dptD genes). Whole subunit exchange was achieved by
deleting the dptD gene and replacing it with either the cdaPS3 or the lptD genes from the CDA
and A45145 synthesis pathways, respectively (dashed box in Figure 1.18). This yielded dapto-
mycin analogues with Kyn-13 substituted by Trp-13 or with ILe/Val-13. The ambiguity in the
latter case is due to the flexibility in substrate recognition for LptD.13, 38, 131
With the help of module or domain substitutions, the amino acids incorporated by DapBC
can be manipulated as well. The substituted module and domain sequences could be derived
from either homologous or heterologous genes. During this process, the target sequence is
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spliced out and the new sequence is introduced by fusing between the splicing sites. The
homologous substitution was exemplified by the changes made on D-Ala-8 and D-Ser-11 within
DapBC, which could be achieved by swapping the whole modules 8 and 11 or only their
respective C-A-T domains. These exchanges produced variants with either or both of D-Ala-11
and D-Ser-8153 (dashed line arrows in Figure 1.18). To replace D-Ala-8, D-Ser-11, and Kyn-13
with D-Asn, the sequence from homologous module-11 in A54145 lptC gene was introduced.
Multiple modules can be exchanged concurrently as well. An analogue containing both D-Lys-
8 and D-Asn-11 was produced when modules 8-11 from dptBC were replaced with modules
8-11 from lptC. In this analogue, the methoxylation on Asp-9 was found to be missing, which
may have been caused by the lack of a tailoring enzyme gene.51, 153
The third variation is the deletion of the dptI gene, located downstream of the major NRPS
genes, which leads to the production of analogues containing Glu-12 instead of MeGlu-12.152
The number of peptide analogues obtained by recombinant techniques is then multiplied
by the natural or precursed variations of lipid tails. In order to facilitate the final purification
process, specific acyl tail precursors (such as n-decanoic acid for daptomycin) are fed to the
fermentation process.
1.4.1.3 Chemoenzymatic synthesis. A major difficulty in the total synthesis of daptomycin
is the formation of the ring-closing ester bond. One elegant strategy to overcome this obstacle
consists in chemoenzymatic synthesis. This approach starts with solid-phase peptide synthesis,
which replaces the natural peptide assembling by NRPSs. This yields a linear peptide, which
is then cyclized using the natural thioesterase (Te domain). It has been shown that excised
Te domains are capable of cyclizing a broad range of substrate peptides.101 During the pro-
cess of synthesizing daptomycin analogues, the Te domain from CDA was used.77 Daptomycin
generated by this method has the same activity as the native compound.166 Although chemoen-
zymatic synthesis provides more options for substituting amino acids and provides sufficient
material for experimental study, it does not scale to the amounts required for clinical use.
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1.4.1.4 Total chemical synthesis. One may wonder why more use has not been made of total
chemical synthesis, which should be able to provide even more analogues. This is because all
reported attempts have found this to be very difficult. The formation of the crucial ester linkage
in daptomycin is especially challenging. Lam and colleagues synthesized daptomycin by using
a combination of solution- and solid-phase chemistry.108 To solve the ester link challenge, they
first synthesized a branched tetradepsipeptide (consisting of Asp, Thr, Kyn, and Gly) in solution
via a 12-step synthesis. The depsipeptide was then bound to a solid support for extension, and
the final step of cyclization was completed in solution-phase again. This combined-phase
method requires multiple HPLC purifications, which makes it very labour-intensive.
Very recently, Lohani, Taylor, and colleagues at the University of Waterloo have success-
fully synthesized daptomycin and a few analogues by entirely using solid-phase synthesis,
which uses a combination α-azido and Fmoc amino acids. This novel approach has already
yielded several derivatives with interesting properties (submitted for publication).
1.4.2 Clinical trials and applications
The initial clinical trials on daptomycin did not go quite as well as the preclinical studies. A
treatment regimen involving two daily doses resulted in unacceptable adverse effects in the
phase 2 trial. This result led to the termination of the daptomycin project by Eli Lilly. Almost
a decade later, Cubist acquired the rights to the drug from Eli Lilly and initiated another round
of clinical trials. The amount of drug applied in these trials was the same as before, but it was
applied in a single daily dose instead of two. This counter intuitive approach turned out to be
successful in reducing adverse effects and was the key to future approval.59
Before the clinical introduction of daptomycin a decade ago, the first choice drug used in
treatment for known or suspected MRSA infections was vancomycin. Since then, daptomycin
has been used with increasing frequency as a primary drug. Some recent studies have sug-
gested that daptomycin might even be a better choice than vancomycin for treating MRSA
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bloodstream infections. It was found to be associated with lower mortality rate and fewer cases
of persistent infections.140, 147
Daptomycin has also proven valuable for “salvage treatment” for vancomycin, meaning
that it has been used successfully after initial treatment with vancomycin had failed. Other
options for treatment of VRE infections include linezolid and quinupristin-dalfopristin.91, 117
Both linezolid and quinupristin-dalfopristin have severe side effects, which limits their utility
in long-term treatment.170 However, daptomycin also has a shortcoming of its own: it is not
effective for treating pneumonia. This has been attributed to pulmonary surfactant, which is
assumed to bind and sequester daptomycin.183
1.4.3 Mode of action
Since the discovery of daptomycin, many studies have attempted to elucidate its mode of ac-
tion, and several different mechanisms have been proposed. While all studies agree that the
antibacterial activity of daptomycin is Ca++-dependent, most other aspects are subject to on-
going debate. To make it easier to follow, the proposed action modes can be divided into two
general categories, namely, disruption of the cell membrane vs. inhibited synthesis of cell wall
macromolecules, specifically peptidoglycan and lipoteichoic acids.
Allen and colleagues first suggested that daptomycin exerts its bactericidal activity through
inhibiting the biosynthesis of peptidoglycan, and more specifically the early cytoplasmic stages
of precursor synthesis. In their initial report,6 they compared the cellular effects of daptomy-
cin with those of other antibiotics known to inhibit peptidoglycan biosynthesis, namely, van-
comycin, amphomycin, and fosfomycin (see Figure 1.2). Unlike vancomycin or amphomycin,
daptomycin did not cause the accumulation of UDP-MurNAc-pentapeptide inside S. aureus
cells. A later study confirmed this observation and also showed that daptomycin did not in-
hibit the synthesis of lipid I and II (Step 3 and 4 in Figure 1.2).174 Collectively, these findings
indicate that any interference of daptomycin with murein synthesis would have to take place
at a very early stage. Indeed, Allen et al. showed that daptomycin inhibited the synthesis of
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UDP-MurNAc, an effect that is also seen with fosfomycin. While Allen did not identify a spe-
cific molecular target, they proposed that daptomycin inhibits the formation of early precursor
molecules for peptidoglycan biosynthesis.6
This initial hypothesis was challenged by Boaretti and colleagues, who claimed that dap-
tomycin binds to bacterial cell membrane irreversibly, which would prevent it from reaching
any of the cytoplasmic targets that are involved in the synthesis of peptidoglycan precursor
molecules.31 Allen and colleagues later revised their initial suggestion. They found that dapto-
mycin does not affect the activity of enzymes that are involved in the synthesis of peptidoglycan
precursor molecules; instead, daptomycin stopped the uptake of amino acids.5 They also no-
ticed that daptomycin causes the release of intracellular potassium6 and the dissipation of the
membrane potential.3 Combining all these findings, they proposed that the target for daptomy-
cin is the energized cell membrane, and the inhibition of cell wall synthesis results from the
disruption of membrane potential and energy metabolism by daptomycin.
Boaretti and colleagues also provided evidence that daptomycin has a stronger inhibitory
effect on the synthesis of lipoteichoic acid than on that of other macromolecules, such as DNA,
RNA, proteins, and peptidoglycan, which led them to propose that lipoteichoic acid (LTA) is
the primary target for daptomycin.31 More experiments were performed to support their claim,
but the results were not convincing. They tested the activity of daptomycin on Enterococcus
faecium protoplasts.21 Protoplasts are cells with their cell wall removed. If an antibiotic only
finds its target in the cell wall, it should have little effect on them. Their result showed dapto-
mycin at MIC killed 99% of the cells within 60 minutes, while killing by vancomycin in the
same time period was negligible. The opposite effects indicate the target for daptomycin might
not be found in the cell wall as for vancomycin, but this was not addressed by the authors. At
the same time, they showed that daptomycin has the strongest inhibitory effect on the synthesis
of LTA during protoplast cell regeneration. Later on, they tried to identify the specific enzyme
targets in cell membrane. Daptomycin was shown to bind to five proteins,20 but none of these
has been identified or shown to be involved in the synthesis of LTA.
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The hypothetical inhibition of LTA biosynthesis was addressed again by Laganas and col-
leagues.105 In their kinetic study, daptomycin was able to inhibit the synthesis of various
macromolecules including RNA, LTA, and lipids, but the inhibition showed no kinetic pref-
erence for LTA biosynthesis. In the control experiment, rifampicin, an inhibitor to RNA
polymerase, demonstrated clear kinetic specificity for RNA biosynthesis. Hence, it was sug-
gested LTA biosynthesis was not the primary target. Laganas et al. also examined the effect
of daptomycin on cells arrested in growth, where all macromolecular biosynthesis pathways
are stopped. If daptomycin’s activity required ongoing synthesis of LTA or any other macro-
molecules, it should not have any effect on these growth-arrested cells. In contrast to this
prediction, it was observed that daptomycin was still very effective in killing these cells. It
was also shown that adding exogenous LTA in excess did not affect the activity of daptomycin,
which suggested daptomycin does not bind to LTA.
Despite their different views, all authors agree that the cell membrane is involved in the ac-
tion mode of daptomycin. Artificial membrane studies showed that daptomycin could bind and
insert into membrane without protein components.107 Silverman and colleagues demonstrated
that daptomycin’s rapid bactericidal activity is closely correlated with the dissipation of the cell
membrane potential, and that daptomycin triggers the release of K+. Based on these findings,
as well as on the similarity to other membrane-damaging molecules, a multi-step mechanism
of action, with the cell membrane as the primary target, was proposed184 (Figure 1.19). Ac-
cording to this mechanism, (1) monomeric daptomycin monomer binds to the membrane in
the presence of Ca++, (2) bound daptomycin monomers oligomerize, and (3) oligomers form
discrete channels to release K+ and cause cell death.
Several later findings strongly supported this model and provided more details. The con-
tent of lipid phosphatidylglycerol (PG) in the bacterial cell membrane is crucial for dapto-
mycin’s bactericidal activity, and a reduced abundance of PG can give rise to daptomycin
resistance.72, 78, 79 Fluorescence studies done on liposome models and on bacterial membrane
vesicles showed that daptomycin, at concentrations similar to those required for antibacterial
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Ca2+
Ca2+
Daptomycin
1 2 3
Figure 1.19 Proposed action mode of daptomycin. In the presence of Ca++, monomeric daptomycin
binds to a susceptible membrane (1); the bound daptomycin monomers oligomerize (2); oligomers
form discrete ion channels (3).184
activity and with physiological levels of Ca++, can bind and form oligomers with 6–7 subunits
on liposomes containing PG. Although daptomycin can bind to liposomes without PG (con-
taining phosphatidylcholine only), this requires much higher than physiological concentrations
of Ca++, and it does not result in oligomer formation.142–144
A modified model, based mostly on NMR studies,85, 95, 194 suggested the calcium-depen-
dent formation of micellar daptomycin oligomers with 14–16 subunits already in solution,
before the interaction with membranes. These micelles are envisaged to approach the bacterial
membrane and dissociate, where individual daptomycin molecules start to insert into the mem-
brane. It should be noted that the concentration of daptomycin used in these NMR experiments
(2mM) were much higher than the minimum inhibitory concentration i (MIC) (v0.5µM). The
above-mentioned fluorescence study144 did not observe oligomerization in solution at concen-
trations close to MIC, which suggests that micelle formation occurs only at high concentration
and is not relevant to the bactericidal mechanism.
While Muraih et al. showed the formation of oligomers on model membranes and bacterial
cells, it should be noted that, up to this point, there was no direct evidence to show if these
oligomers are involved in membrane permeabilization. Cotroneo and colleagues found that
iMinimum inhibitory concentration: the lowest concentration of an antimicrobial that will inhibit the growth
of a microorganism after overnight incubation.
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daptomycin kills S. aureus cells without causing cell lysis or any membrane discontinuities
visible by electron microscopy,41 which favors the formation of small and discrete pores. They
also noticed daptomycin altered cell wall morphology with abnormal septation events.
Another group also characterized daptomycin-mediated alterations in cell morphology.
Pogliano and colleagues showed that daptomycin induces curved membrane patches that at-
tract the bacterial protein DivIVA.164 DivIVA is involved in cell wall synthesis by recruiting
other cell division enzymes. The correlation between daptomycin binding, localization of Di-
vIVA, and altered cell morphology led them to propose a new twist on Silverman’s model.
When daptomycin is applied at a sub-lethal concentration, the daptomycin aggregates induce
limited local alterations of cell morphology that become visible as cell bending and abnor-
mal septations. When a lethal dose of daptomycin is given, multiple local alterations of the
membrane are induced, which overwhelms the cells’ ability to compensate. Certain small dis-
continuities on membrane might start to appear, which causes the leakage of ions and loss of
membrane potential.
1.4.4 Resistance to daptomycin
As has been mentioned earlier, many variants of bacterial resistance have arisen through hor-
izontal gene transfer. Although there is no such case reported regarding daptomycin, some of
the potential sources of resistance genes have been investigated.
There is a gene, dptP, located very close to the synthetase gene cluster, which encodes a
very basic protein (pI >11.5). It is assumed that this basic protein could directly neutralize the
acidic daptomycin before transport.14
Among some of the daptomycin-resistant actinomycete isolates, daptomycin was found to
be inactivated by hydrolysis of the ring-closing depsipeptide bond or by hydrolytic cleavage of
the lipid tail. The inactivation of daptomycin by Paenibacillus lautus was found specifically
caused by hydrolysis of the ring-closing ester bond.19, 46 It is possible that the genes encoding
these hydrolases could find their way to pathogenic bacteria.
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In order to elucidate the resistance mechanisms in the clinical and laboratory-derived iso-
lates, a number of hypotheses have since been proposed based on phenotypic observations and
on DNA sequencing. All of them suggest that the bacteria gained their resistance through
adaptation in cell wall homeostasis and membrane phospholipid metabolism.
One morphological characteristic observed in some daptomycin-resistant isolates is the
thickening of cell walls.10, 137, 190 It has been suggested that such thickened walls act as rein-
forced physical barriers to impede access of daptomycin to its membrane targets. A number of
genes in cell wall synthesis and metabolism were found to be upregulated following exposure
to daptomycin.68, 148 Many of these genes are regulated by an essential YycFG regulatory sys-
tem.52, 53 Mutations in YycFG have been identified in many daptomycin-resistant strains.72, 89
It is possible that the thickened call wall is the result of these mutations after a prolonged
exposure to daptomycin.
Many of these genes are under the control of vraSR regulator, which is also upregulated.
By inactivating vraSR, daptomycin-resistant S. aureus could be reverted back to a susceptible
phenotype, which coincided with the restoration of a thinner cell wall.129
The modification of the cell wall is not just limited to an increase in thickness. The overex-
pression of the dlt operon has been linked to daptomycin resistance. The dlt operon is respon-
sible for the D-alanylation of wall teichoic acids, and its overexpression was shown to correlate
with increased positive surface charge and reduced daptomycin binding to cells. Based on this
observation, it was suggested that resistance might result from electrostatic repulsion between
cell wall and daptomycin-Ca++ complex.221 However, it is noteworthy that daptomycin is nega-
tively charged in solution, and that the cationic daptomycin-Ca++ complex might not form until
it is in very close proximity with the target membrane, at which point it would have already
passed the cell wall. In a study on a resistant S. aureus strain with thickened cell walls, Bertsche
and colleagues18 showed enhanced transcription of both the tag and dlt operons, which are re-
sponsible for the production of wall teichoic acid and for its D-alanylation, respectively. They
suggested that resistance could be the result of multiple cell wall modifications. Hence, it
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is possible that the resistance is due to the limited access to membrane conferred by a more
densely packed cell wall.171
Changes in the fluidity of the cell membrane is also seen in some resistant S. aureus strains.
The clinical resistant isolates tend to have more fluid membranes than their susceptible parental
strains, whereas the ones selected by serial passaging in the laboratory tend to have more
rigid membranes than their parental strains.91, 93, 137 The cell membrane fluidity is directly
affected by the content of carotenoids. It has been shown that the increased production of
carotenoid correlated with increased daptomycin MICs and enhanced membrane rigidity.135
Nevertheless, strains that lack carotenoids have very fluid membranes and are also resistant to
daptomycin.16, 87 These contradicting observations were described as a “Goldilocks effect”,
such that, for optimal activity for daptomycin, the membrane could be neither too fluid nor too
rigid.16, 91 However, how the membrane fluidity affects daptomycin activity at the molecular
level is still unknown.
Mutations in the mprF gene are also found in many resistant S. aureus strains.72 This gene
encodes a dual-functional membrane enzyme that catalyzes both the conversion of PG to lysyl-
PG (Figure 1.20) in the inner leaflet of the membrane and the subsequent translocation to the
outer leaflet.64 The mutant enzymes found in resistant strains showed gains in function, which
either increase the production of lysyl-PG or accelerate the flipping, which all result in an
increase of lysyl-PG content in the outer membrane leaflet.93, 163 Since lysyl-PG is positively
charged, it has been suggested that the resistance could be the result of increased charge-charge
repulsion to cationic daptomycin-Ca++ complex, a similar mechanism as suggested for overex-
pression of dlt operon. It is also possible that the main effect of increased lysyl-PG synthesis
is the concomitant reduction of PG in the membrane, which reduces the binding sites for dap-
tomycin.79
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Figure 1.20 Chemical structures of lipid molecules: left, phosphatidylglycerol (PG), middle, car-
diolipin (CL), and right, lysyl-phosphatidylglycerol (lysyl-PG). One CL molecule is synthesized by
condensing two PG molecules. Lysyl-PG is produced by modifying the head group of PG. Dapto-
mycin’s activity depends on the membrane content of PG. The increased content of either CL or
lysyl-PG (outer leaflet) has been suggested to cause resistance.
1.5 RESEARCH OBJECTIVES
Up to this point, ion channel formation is the best-defined and -supported model to explain
daptomycin’s mechanism of action. However, there are still many important questions that
need to be answered by experiments. This thesis aimed to answer some of them.
1. Fluorescence studies have shown that daptomycin forms oligomers on liposome mem-
branes and also on the cell membranes of susceptible bacteria. While oligomerization is
thought to be required for bactericidal activity, this has not been experimentally demon-
strated. This question is addressed in Chapter 2.
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2. Daptomycin’s rapid bactericidal activity correlates with membrane depolarization, which
has been ascribed to permeabilization of the membrane toward K+.184 However, the
concentration of K+ is higher inside the cell than outside, and a selective permeabilization
for K+ should cause hyperpolarization rather than depolarization. This suggests that the
daptomycin permeabilizes the membrane toward ions other than K+ also. Experiments
that shed light on this question are presented in Chapter 3.
3. Apart from lysyl-PG, another lipid involved in resistance is cardiolipin (Figure 1.20),
which is formed by condensing two PG molecules. Resistant Enterococcus strains were
found to have mutations that enhance cardiolipin synthase activity.44, 158 Does cardi-
olipin interact directly with daptomycin, and if so, how? This question is examined in
Chapter 4.
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Chapter 2
The role of oligomer formation in the antibacterial activity of
daptomycin
2.1 INTRODUCTION
The lipopeptide antibiotic daptomycin is used clinically against infections by Gram-positive
bacteria, including strains of staphylococci and enterococci that are resistant to other antibi-
otics.17, 32, 199 It binds to and causes depolarization of the bacterial cytoplasmic membrane,
which is considered to be the mechanism of its rapid bactericidal action.3, 184 Electron mi-
croscopy of daptomycin-exposed cells does not reveal any discontinuity of the lipid bilayer.41
Both this observation and the selective nature of the membrane permeability defect5 support
the notion that daptomycin forms small, discrete membrane lesions. It was proposed earlier
The results presented in this chapter have been published in: “Mutual inhibition through hybrid oligomer
formation of daptomycin and the semisynthetic lipopeptide antibiotic CB-182,462”, by Tianhua Zhang, Jawad
K. Muraih, Evan Mintzer, Nasim Tishbi, Celine Desert, Jared Silverman, Scott Taylor, and Michael Palmer(2013),
Biochim. Biophys. Acta 1828:302-8.
Authors’ contributions: The experiment depicted in Figure 2.4 was performed by E. Mintzer and N. Tishbi.
The synthesis and purification of perylene-daptomycin were performed by S. Taylor. All other experiments were
done by the thesis author. The experiments depicted in Figure 2.6 were replicated by J. Muraih.
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Figure 2.1 Structures of daptomycin and of CB-182,462 and of their labeled derivatives used in this
study. Arrows indicate amide or ester bonds, in C to N or C to O direction. In perylene-daptomycin,
a perylene-butanoyl residue replaces the N-terminally attached decanoyl residue found in dap-
tomycin. CB-182,462 is a semisynthetic derivative of the natural compound A54145, in which
the naturally occurring N-terminally linked fatty acyl residue is replaced by a substituted carbamyl
residue. In NBD-CB-182,462, a nitrobenzoxadiazole (NBD) group is attached to the free amine
in the side chain of D-lysine. Abbreviated names for non-standard amino acids: Orn, ornithine;
MeOGlu, γ-methoxy-glutamate; kyn, kynurenine; HO-Asn, β -hydroxy-asparagine; MeOAsp, β -
methoxy-aspartate. The two residues whose intrinsic fluorescence was used in some of the exper-
iments, tryptophan in CB-182,462 and kynurenine in daptomycin, are set in boldface. Note that,
in addition to the sequence similarity, the same positions are occupied by D- and L-amino acids in
both molecules.
that these discrete lesions are formed by oligomeric assemblies of daptomycin molecules.184
However, experimental evidence of oligomer formation has been obtained only recently,142, 144
and direct proof of their involvement in membrane permeabilization is still lacking.
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Daptomycin and antibiotic A54145 share the same architecture: both consist of 13 amino
acids, including several non-standard ones (Figure 2.1).23, 49 The ten C-terminal residues form
a ring that is closed by an ester bond. The exocyclic N-terminal tryptophan carries a fatty acyl
residue, which in the clinical drug preparation for daptomycin is decanoic acid, although the
length of this acyl tail is subject to variation in the natural product. The two molecules also
share significant sequence homology, with five identical residues and four more similar ones.
We reasoned that testing the two molecules for their ability to form hybrid oligomers should
provide information on the contributions of the conserved and the non-conserved residues,
respectively, to the oligomerization process.
The experiments were performed with various fluorescent derivatives of daptomycin and
of CB-182,462, a semisynthetic derivative of A54145.124 Our results readily demonstrate the
formation of such hybrid oligomers, both on model membranes and on bacterial cells; there-
fore, the amino acid residues conserved between daptomycin and CB-182,462 are sufficient
for oligomerization. Remarkably, however, the hybrid oligomers exhibit reduced antibacterial
activity. The observation of oligomers with impaired antibacterial activity shows, on the one
hand, that the oligomer is indeed involved in the antibacterial effect. On the other hand, it indi-
cates that oligomer formation as such is not sufficient for activity. Upon assembly, the oligomer
must undergo some additional event, such as for example cooperative membrane insertion or
the adoption of a very specific structure, in order to acquire bactericidal activity.
2.2 MATERIALS AND METHODS
2.2.1 Synthesis and purification of NBD-CB-182,462 and of perylene-daptomycin
Unlabeled CB-182,462 was provided by Cubist Pharmaceuticals Inc. (Lexington, MA, USA).
Reaction of CB-182,462 with NBD-Cl (4-Chloro,7-nitro-2,1,3-benzoxadiazole; Fluka) and
HPLC purification were performed as described before for NBD-daptomycin.144 Molecular
weight and homogeneity were confirmed by mass spectrometry on a Micromass Q-TOF Ul-
55
2 The role of oligomer formation in the antibacterial activity of daptomycin
tima GLOBAL mass spectrometer. The synthesis of perylene-daptomycin has been described
as well.142
2.2.2 Preparation of PC/PG large unilamellar vesicles (LUV)
The synthetic lipids 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) and 1,2-dimyrist-
oyl-sn-glycero-3-phospho-rac-(1’-glycerol) (DMPG; both from Avanti Polar Lipids, Alabaster,
AL, USA) were used to prepare the vesicles. Equimolar amounts of DMPC and DMPG were
weighed into a round-bottom flask and dissolved in chloroform/methanol (3:1). The solvent
mixture was then evaporated with nitrogen to produce a lipid film, which was further dried
under vacuum for 3 h and then dispersed in buffer. The resulting lipid suspension was ex-
truded through a 100 nm polycarbonate filter 15 times, using a nitrogen-pressurized extruder
to produce indicator-loaded large unilamellar liposomes126, 144
2.2.3 Isothermal titration calorimetry (ITC)
Binding of daptomycin, of CB-182,462, and of a 1/1 (mol) mixture of the two to lipid vesi-
cles was measured calorimetrically at 25 °C using a VP-ITC from Microcal (GE Healthcare,
Northampton, MA). LUV for this assay were prepared from equimolar dioleoyl-PG (DOPG)
and dioleoyl-PC (DOPC) (5 mM total lipid) in buffer (10 mM HEPES, 100 mM sodium chlo-
ride, 1 mM CaCl2 pH 7.4) by the freeze–thaw/extrusion method. Lipopeptides were dissolved
in the same buffer. In a typical ITC experiment, the sample cell was filled with 23 µM lipopep-
tide solution and the reference cell with buffer. The 250 µL titration syringe was loaded with
LUV suspension. Solutions and suspensions were degassed with stirring for 10 min prior to
titrations. After system equilibration and a stable baseline was achieved, a1 µL aliquot of LUV
suspension was injected, the heat signal of which was excluded from data analysis according
to the instrument’s manufacturer’s recommendation, followed by 2.5 µL injections at 6 min
intervals until several successive injections generated low and constant heat signals. The cell
contents were stirred by the injection syringe throughout the titration at a rate of 270 rpm.
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Heat resulting from LUV dilution into buffer, which was small and constant (data not shown),
was subtracted, and the baseline was adjusted manually to the average noise value prior to
data analysis.82 Data were collected and analyzed using proprietary Origin software provided
by Microcal. Thermodynamic parameters were derived from least squares analysis of the in-
tegrated heat signals using Origin’s one-site model curve fitting routine. Experiments were
performed at least in triplicate and derived parameters were reproducible within 15%.
2.2.4 Steady-state fluorescence measurements on PC/PG liposomes and on bacterial cells
Fluorescence emission spectra were acquired using a PTI QuantaMaster spectrofluorometer.
Excitation wavelengths were 282 nm for tryptophan, 430 nm for perylene, and 465 nm for
directly excited NBD fluorescence. Excitation and emission band passes were typically 2 nm
but were occasionally adjusted in order to increase or reduce sensitivity. Unlabeled daptomycin
and CB-182,462 or NBD-labeled CB-182,462 and perylene-labeled daptomycin were applied
in the quantities indicated in the Results section (2.3) to the liposomes (200 or 250 µM total
lipid) in HEPES/NaCl with calcium (5 mM). Samples were incubated for 5 or 10 min before
acquisition of emission spectra, and in some instances measured repeatedly after longer time
intervals as indicated.
For fluorescence measurements on bacteria, cells from a fresh overnight culture of Bacil-
lus subtilis ATCC 1046 were harvested and repeatedly washed with HEPES/NaCl buffer by
centrifugation in a table-top centrifuge. The pelleted cells were resuspended in approximately
20 volumes of buffer. Of the resulting cell suspension, 150 µL were incubated in the pres-
ence of CaCl2 (5 mM) for 10 min with the amounts of labeled or unlabeled daptomycin and
CB-182,462 stated in the Results section (2.3). The cells were again washed repeatedly by
centrifugation with HEPES/NaCl/CaCl2, resuspended in the same buffer and measured as de-
scribed above for liposome samples.
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2.2.5 Antibacterial activity of daptomycin and CB-182,462
Overnight cultures of Bacillus subtilis ATCC 1046 were grown at 37 °C in LB broth. Dap-
tomycin and CB-182,462, alone or combined in various ratios, were serially diluted in LB
broth supplemented with 5 mM CaCl2 (the mixing ratios and dilutions are depicted in Figure
2.6 on page 65). Each serial dilution was inoculated with 1% by volume of the Bacillus sub-
tilis overnight culture, and the culture tubes were incubated with shaking at 37 °C overnight.
Growth was evaluated visually by turbidity. The transition from translucency (that is, inhibi-
tion) to high turbidity (growth) usually occurred abruptly. When intermediate turbidity was
observed, which occurred at the most once in any given dilution series, the concentration in
question was considered not inhibitory; that is, the minimum inhibitory concentration (MIC)
was taken to be the lowest concentration without any visible turbidity. Growth and sterility
controls were included in each experiment.
2.3 RESULTS
2.3.1 Oligomerization of CB-182,462 on liposome membranes
We have previously shown that daptomycin forms oligomers on model membranes and bacte-
rial cells.142–144 While the similarity between the two compounds suggests that CB-182,462
should do the same, this has not been directly demonstrated. Therefore, a fluorescently labeled
derivative was prepared with nitrobenzoxadiazole (NBD) attached to its unique free amino
group (Figure 2.1). While the absorption of NBD is highest around 470 nm, there is a smaller
absorption peak around 340 nm110 that overlaps the fluorescence emission spectrum of tryp-
tophan. This allows the detection of FRET between the tryptophan of unlabeled CB-182,462
and the NBD-labeled derivative. In the experiment shown in Figure 2.2A, the two species
were mixed before application to PC/PG liposomes in the presence of calcium. The tryptophan
fluorescence of the unlabeled molecules is very strongly reduced by FRET, which indicates a
close association of the two species. FRET is still observed, but to a lesser extent, when the
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Figure 2.2 Formation of CB-182,462 oligomers on PC/PG liposomes. NBD-labeled CB-182,462
(0.96 µM) and unlabeled CB-182,462 (4.8 µM), alone or combination, were incubated with PC/PG
(1:1, 200 µM total lipid) liposomes in the presence of calcium (5 mM). A: Tryptophan fluorescence
upon excitation at 282 nm. NBD-CB-182,462 has virtually none, due to FRET from tryptophan to
NBD. When the two compounds are mixed before application to liposomes, the tryptophan fluo-
rescence is more strongly quenched than when they are applied separately with a time interval of
5 min between both applications. This is consistent with the formation of hybrid oligomers in the
first case but mostly segregated oligomers in the second. The emission of NBD was not scanned
in this experiment because it overlaps the secondary maximum of the excitation wavelength. B:
Self-quenching of NBD-CB-182,462. Addition of unlabeled CB-182,462 before application to the
PC/PG liposomes increases the fluorescence intensity of NBD-CB-182,462 upon direct excitation
of NBD at 465 nm, indicating that the latter is subject to self-quenching in homogeneous oligomers.
If the unlabeled CB-182,462 is added 5 min after the NBD-labeled sample, it has little effect on the
extent of quenching.
two species are applied sequentially. Under these conditions, the labeled molecules and the un-
labeled ones should undergo oligomerization separately, and therefore FRET will only occur
between, but not within oligomers, which accounts for the reduced overall extent of FRET.
NBD exhibits concentration-dependent self-quenching.27 The local concentration of NBD
is higher, and therefore quenching is more pronounced, in pure NBD-CB-182,462 oligomers
than in hybrid oligomers formed from a mixture of the NBD-labeled compound and an excess
of the unlabeled one (Figure 2.2B). The results from both FRET and self-quenching experi-
ments are completely analogous to our previous observations with daptomycin.144
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Figure 2.3 Formation of hybrid oligomers of native CB-182,462 and daptomycin on liposomes. A:
When both compounds (2 µM each) are mixed before addition to PC/PG liposomes (250 µM total
lipid) and calcium (5 mM), the tryptophan fluorescence of CB-182,462 is strongly reduced by FRET,
and the kynurenine emission of daptomycin (around 445 nm) is increased. The extent of FRET is
smaller when one compound is applied to the liposomes 5 min after the first one. B: Extended
incubation of a sequentially prepared sample. The extent of FRET increases slightly with time,
but after 60 min still does not approach that of a premixed sample, indicating that daptomycin and
CB-182,462 mostly do not reassemble into hybrid oligomers within this time period. Thin yellow
lines represent several time points between 5 and 60 min.
2.3.2 Formation of daptomycin/CB-182,462 hybrid oligomers on liposomes
The intrinsic fluorescence of tryptophan also overlaps the absorption spectrum of kynure-
nine, which in daptomycin causes virtually complete FRET from tryptophan to kynurenine.107
FRET between tryptophan and kynurenine can also be used to detect formation of hybrid CB-
182,462/daptomycin oligomers. When a premixed sample of the two is applied to PC/PG
liposomes, the tryptophan fluorescence of CB-182,462 is largely suppressed by FRET (Fig-
ure 2.3A). Again, sequential application reduces FRET, which is consistent with formation of
separate oligomers.
While daptomycin oligomers are largely stable on a time scale of one or a few hours,144
it seems possible that hybrid oligomers of CB-182,462 might be less stable. In the experi-
ment shown in Figure 2.3B, a sample prepared by sequential application of the two antibiotics
was incubated, and the fluorescence emission measured repeatedly after various time intervals.
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While the extent of FRET increases slightly with time, it remains much lower than that ob-
served with a premixed sample after 60 min. This suggests that the rate of subunit exchange
between oligomers is low, and oligomers are largely stable on the time scale of the experiment.
The stability of the hybrid oligomers was also examined by ITC. Figure 2.4 shows the
ITC traces of daptomycin alone (A), CB-182,462 alone (C) and of an equimolar mixture (B)
titrated with liposomes, which were prepared from an equimolar mixture of DOPC and DOPG.
In all cases, early injections result in exothermic heat signals, which gradually decrease to
very low spikes that represent heat of LUV dilution. Integration of the heat signals from these
experiments produce the sigmoid curves typical for ITC experiments in which binding between
membrane and drugs is specific and saturable. The titration profiles and the calculated energy
terms for ∆H, T∆S and ∆G (Figure 2.4D) are quite similar between the pure daptomycin and
CB-182,462 samples on the one hand, and the equimolar mixture on the other, which supports
the notion that the hybrid oligomers resemble the pure ones with respect to thermodynamic
stability.
Another interesting aspect of the ITC results is the observed stoichiometry of the lipopep-
tides and phosphatidylglycerol, which is very close to 2 molecules of PG for each molecule of
antibiotic. In a previous study using perylene excimer fluorescence and lipid bicelles, a stoi-
chiometry of 1 was observed.142 One possible explanation for the discrepancy is that, in the
liposome system, the lipopeptides interact only with the outer monolayer. Alternatively, it is
possible that excimer fluorescence and thermal changes report on different stages of the mem-
brane interaction that require only one and two molecules of PG, respectively. This question
requires further study.
2.3.3 Formation of hybrid oligomers on bacterial cells
While PC/PG membranes are a useful model to observe the activity of daptomycin and CB-
182,462, the lipid composition of bacterial membranes is different, and it is therefore pertinent
to examine the formation of hybrid oligomers on bacterial cells as well. Due to the abundance
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Figure 2.4 Interaction of homogeneous and hybrid oligomers with DOPC/DOPG membranes, stud-
ied with isothermal calorimetry (ITC). A–C: Raw ITC heat signals (top panels) and corresponding in-
tegrated isotherms (bottom panels) for titrations of pure daptomycin (A), equimolar daptomycin/CB-
182,462 hybrids (B), and pure CB-182,462 (C) with 1/1 (mol/mol) PG/PC liposomes at 25 °C. Solid
lines are best-fit curves obtained with Microcal’s Origin single binding site model. D: Summary
of thermodynamic binding parameters. All experiments were performed at least in triplicate and
results were reproducible within 15%. Representative isotherms are shown.
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Figure 2.5 Formation of hybrid CB-182,462 oligomers on Bacillus subtilis cell membranes. A:
Alleviation of NBD-CB-182,462 self-quenching by unlabeled CB-182,462 or daptomycin. NBD-
CB-182,462 (4 µM), alone or premixed with unlabeled CB-182,462 or daptomycin (20 µM),was
incubated with Bacillus subtilis ATCC 1046 cells in the presence of calcium(5 mM). After incuba-
tion for 10 min, the cells were washed repeatedly by centrifugation, resuspended in buffer, and
the NBD fluorescence measured upon excitation at 465 nm. B: Inhibition of excimer formation by
perylene-daptomycin by unlabeled daptomycin or CB-182,462. Perylene-daptomycin monomers
emit maximally at 455 nm, whereas the excimers emit maximally at about 525 nm.142 Concentra-
tions of labeled and unlabeled compounds, and other conditions were the same as in A.
of tryptophan in bacterial proteins, the intrinsic tryptophan fluorescence of CB-182,462 could
not be used in these experiments. However, however, two alternative approaches allowed for
the detection of hybrid oligomers on Bacillus subtilis cells.
In the first experiment (Figure 2.5A), the concentration-dependent self-quenching of NBD
in NBD-labeled CB-182,462 was inhibited not only by unlabeled CB-182,462 but also using
unlabeled daptomycin, which means daptomycin subunits intercalate between and separate the
labeled molecules. In the second experiment (Figure 2.5B), the formation of perylene excimers
in oligomers of perylene-labeled daptomycin142 is suppressed by both unlabeled daptomycin
and unlabeled CB-182,462.
Between the two experiments, it is evident that both the labeled and the unlabeled forms
of daptomycin and CB-182,462 are capable of hybrid oligomer formation on bacterial cell
membranes.
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2.3.4 Antibacterial activity of daptomycin/CB-182,462 mixtures
If two different drugs act independently but share the same target and mode of action, their
mixtures will display additive effectiveness. This can be detected by isobolographic analysis.73
In such an experiment, the concentrations of the two drugs in question are varied independently,
and lines are drawn to connect equieffective dosages of various combinations. If the two drugs
indeed behave additively, the equieffective dosages of all mixtures will fall on a straight line
that also includes the equieffective dosages of the two pure drugs.
Figure 2.6A shows an isobologram for the minimum inhibitory concentrations (MICs) of
daptomycin and CB-182,462. It is clear that the observed MICs deviate from such an ideal
straight line. With the mixtures, greater than additive dosages are required to reach the MIC,
indicating that the two drugs inhibit one another. The discrepancy is greatest with the equimolar
mixture of the two antibiotics, indicating that mutual inhibition is most pronounced at this ratio
(Figure 2.6B). While any binary mixture should produce a distribution of oligomers that vary
with respect to both the fractions of the two antibiotics incorporated and the positions within
the oligomer occupied by each, an equimolar ratio should maximize the extent of scrambling
and minimize the residual fractions of homogeneous oligomers. The observation that mutual
inhibition is strongest at this ratio therefore supports the notion that hybrid oligomers have
impaired antibacterial activity.
2.4 DISCUSSION
In previous studies, it was shown that daptomycin forms oligomers on PG-containing mem-
branes,142, 144 and that the oligomers have a stoichiometry of approximately 6–7 subunits, or
possibly twice that number.143 A role of membrane-associated oligomers in the antibacterial
activity of daptomycin has widely been assumed and accepted as plausible;184 however, direct
experimental evidence has been lacking. The mutual inhibition between daptomycin and the
semisynthetic homologous lipopeptide CB-182,462 reported in this study constitutes the first
64
2 The role of oligomer formation in the antibacterial activity of daptomycin
 0
 0.5
 1
 1.5
 2
 2.5
 3
0 0.25 0.5 0.75 1 1.25
CB
-1
82
,4
62
 (µ
M
)
Daptomycin (µM)
A B
Tested dilutions
MIC
Additivity
 1
 1.25
 1.5
 1.75
 2
0.5 1 2 4
M
IC
o
bs
er
ve
d 
/ M
IC
a
dd
itiv
e
CB-182,462
 
/
 
daptomycin (mol
 
/
 
mol)
Figure 2.6 Mutual inhibition of bactericidal action between daptomycin and CB-182,462. A:
Isobologram of MICs observed in an individual experiment. Daptomycin and CB-182,462 were
admixed in LB medium and serially diluted at the ratios indicated; thin blue lines connect serial
dilutions of the same starting mixture. Bacillus subtilis ATCC 1046 was pre-grown in LB broth and
inoculated 1:100 into each serial dilution. In case of independent and additive action, all MICs
should fall on a straight line connecting those of the pure antibiotics. The observed MICs of the
mixtures deviate toward higher concentrations, indicating mutual inhibition. B: The ratio of the ob-
served MIC to the hypothetical MIC expected from the linear additivity relation was calculated for
each of the indicated mixing ratios. Data represent averages and standard deviations from six
independent experiments. Higher ratios indicate greater mutual inhibition.
such evidence; for if each individual monomer contributed independently and proportionally
to the antibacterial action, combinations of the two antibiotics should display strictly additive
activity.
Considering the number of subunits (at least 6) and the efficiency of FRET between the
two antibiotics (Figure 2.2A), it is likely that the oligomers produced by equimolar mixtures
are indeed mostly hybrids, albeit with varying subunit stoichiometry. According to ITC, these
oligomers have virtually the same stability as the homogeneous ones, which suggests that hy-
brid and homogeneous oligomers are also structurally similar. This is supported by the obser-
vation that equimolar mixtures exhibit only moderately reduced antibacterial activity, which
means that some of the hybrids formed by this mixture are functionally active. Conceivably,
the ones that are not active resemble a “pre-pore” stage that may also transiently exist with
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Figure 2.7 Hypothetical model for daptomycin action. A: Membrane binding (1) precedes oligomer-
ization (2), which in turn must be followed by membrane insertion (3) in order to produce functional
membrane lesions. B: In mixtures of CB-182,462 and daptomycin, oligomerization is preserved,
but membrane insertion and permeabilization may be disrupted.
homogeneous oligomers, and which has to undergo an additional step to acquire bactericidal
activity. A similar functional sequence exists with many pore-forming protein toxins, such as
for example Staphylococcus aureus α-toxin,96, 211 anthrax toxin protective antigen,133 and the
cholesterol-dependent cytolysins of Gram-positive bacteria,88 all of which first assemble into
oligomers atop the target membrane before cooperatively inserting into and then permeabiliz-
ing it. However, this hypothetical scenario, which is depicted in Figure 2.7, clearly needs to be
addressed by further experimental study; it is not known at this time whether or not the inac-
tive hybrid oligomers resemble a kinetic intermediate of the normal, active membrane lesion.
The need for further experiments also pertains to the functional roles of individual amino acid
residues in the daptomycin molecule. While our study makes an initial distinction between two
functional groups of residues—namely, the ones shared between daptomycin and CB-182,462,
which suffice for oligomerization, and those not shared between the two molecules, which
make at least some contribution to oligomer activation—this level of resolution is clearly in-
adequate for construction of a detailed structural and functional model of the formation and
activation of the oligomer. Studies with additional synthetic or genetically engineered151, 195
molecular variants of daptomycin may help to address this question.
The high degree of specificity in the mutual interaction of the subunits within the dapto-
mycin and CB-182,462 oligomers agrees with the considerable stability of the oligomers; even
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the hybrids, which one might expect to be less stable than the homogeneous oligomers, appear
mostly stable on a time scale longer than required for exercising the antibacterial effect.
Daptomycin has been likened to the large and structurally diverse functional family of
antibacterial peptides.136, 194 However, with most antibacterial peptides, oligomer formation
seems to be rather fleeting and transient, or at least more readily reversible25, 29, 176, 177 than with
daptomycin and CB-182,462. It appears possible, therefore, that pore-forming protein toxins
provide a more useful and valid paradigm than typical antimicrobial peptides to understand
daptomycin’s mode of action.
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Chapter 3
Daptomycin forms cation- and size-selective pores in model
membranes
3.1 INTRODUCTION
Daptomycin acts at the bacterial membrane. Various molecular targets and action modes have
been proposed, including the inhibition of peptidoglycan130 or lipoteichoic acid synthesis.31
However, the only effect consistently reported in studies from different laboratories consists
in the depolarization of the bacterial cell membrane.3, 5, 169, 184 Concomitantly with membrane
depolarization, bacterial cells lose the ability to accumulate amino acid substrates, while leav-
ing glucose uptake intact, indicating a selective nature of the membrane permeability defect.5
No membrane discontinuities have been observed by electron microscopy,41 also supporting
the notion that the functional membrane lesion is discrete and small.
The results presented in this chapter have been published in: “Daptomycin forms cation- and size-selective
pores in model membranes”, by TianHua Zhang, Jawad K. Muraih, Ben MacCormick, Jared Silverman, and
Michael Palmer(2014), Biochim. Biophys. Acta 1838:2425-30.
Authors’ contributions: The calculation and fitting depicted in Figure 3.7 was performed by M. Palmer. All
other experiments were done by the thesis author. Some experiments were replicated by B. MacCormick and
J. Muraih.
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Based on precedent from other membrane-damaging peptides and proteins, it was proposed
early on that daptomycin acts through the formation of oligomeric transmembrane pores;184
however, experimental evidence was only obtained more recently. Using various fluorescently
labeled, functionally active daptomycin derivatives, oligomerization was observed both on
model liposomes and on bacterial membranes,142–144 and it was subsequently shown that oli-
gomerization is required for antibacterial action (see Chapter 2). The model liposomes used
in those studies contained only phosphatidylcholine (PC), which is largely inert to daptomy-
cin,144 and phosphatidylglycerol (PG), which was required to induce binding at physiologically
relevant calcium concentration, as well as to trigger oligomer formation.
It is noteworthy that the abundance of phosphatidylglycerol in bacterial cell membranes is
also a major determinant in the susceptibility of bacteria to daptomycin.12, 72, 79 It was there-
fore of interest to determine whether the PC/PG liposome model also suffices to support the
formation of the functional daptomycin pore, and if so, to characterize the pore’s permeability
properties. This study reports the corresponding experiments. The results show that dapto-
mycin forms discrete pores on liposome membranes that are selective for cations of limited
size.
3.2 MATERIALS AND METHODS
3.2.1 Preparation of indicator-loaded large unilamellar vesicles
The procedures for preparing the large unilamellar vesicles have been described in the pre-
ceding charpter (Section 2.2.2). The buffers used for dispersing the lipid film contained either
pyranine or 5,5’-dithiobis-(2-nitrobenzoic acid) (DTNB) as an indicator for the permeabiliza-
tion assays, and they varied in pH and salt composition as detailed in Table 1. Following
polycarbonate membrane extrusion, the liposomes were subjected to gel filtration on a BioGel
P-6DG column (Bio-Rad, Richmond, CA, USA) in order to remove unentrapped indicator.
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Table 3.1 Buffers and indicators used to detect membrane permeabilization toward different so-
lutes. The indicators were dissolved in the corresponding hydration buffer, and the solution was
then used to rehydrate PC/PG lipid films. After extrusion of the lipid dispersion through polycar-
bonate membranes, unentrapped indicator was removed by gel filtration using the corresponding
hydration buffer. In experiments with anionic or cationic test solute, pH gradients were estab-
lished by diluting the liposome samples into reaction buffers with different pH levels. Pyranine (8-
hydroxypyrene-1,3,6-trisulfonic acid) and DTNB (5,5’-dithiobis-(2-nitrobenzoic acid)) were obtained
from Sigma.
Test solutes Hydration buffer Entrapped indicator pH value
Cations 5 mM MES, 5mM Tricine,
5 mM NaCl, 5mM KCl,
250 mM Sucrose
5 mM pyranine 6.00
Anions 5 mM MES, 5mM Tricine,
5 mM NaCl, 5mM KCl,
250 mM Sucrose
5 mM pyranine 8.00
Neutral
solutes
20 mM HEPES, 150 mM
NaCl, 250 mM Sucrose
5 mM pyranine 7.00
The column buffers used in the gel filtration step matched those used for lipid film rehydration,
except for the absence of pyranine or DTNB.
As indicated in Table 3.1, all loading buffers also contained 250 mM sucrose. This exper-
imental detail was adopted from a previous study37 and was found to improve the stability of
the indicator-loaded liposomes.
3.2.2 Fluorescence measurements
With pyranine-loaded liposomes, time-based emission scans were acquired on a PTI Quan-
taMaster 4 system, the sample holder of which was thermostatted at 30 °C. Liposome sus-
pensions were diluted to a final concentration of 250 µM of total lipids into reaction buffer
with 5 mM CaCl2. Daptomycin (Cubist), carbonyl cyanide m-chlorophenyl hydrazine (CCCP,
Sigma), and valinomycin or gramicidin (Sigma) were added as indicated to final concentrations
of 1 µM, 5 nM, 0.5 µM, and 10 nM, respectively, in order to initiate the reaction. The fluo-
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Figure 3.1 Binding of daptomycin to PC/PG membranes under conditions used in permeabilization
assays. The binding of daptomycin to membranes can be monitored using its intrinsic kynurenine
fluorescence as described.107,144 At both pH 6 and pH 8, binding of 1 µM daptomycin reaches
saturation at calcium concentrations lower than 5 mM.
rescence emission at 510 nm was recorded for 5 min, with excitation at 460 nm. Triton X-100
was then added to a final concentration of 0.1%, followed by one more minute of recording;
this was done in order to disrupt the liposomes and so to establish the fluorescence intensity
equivalent to 100% test solute permeation.
With cationic test solutes, the reaction buffer was similar to the corresponding liposome
hydration buffer (see Table 3.1), but the concentration of the test solute was increased to 100
mM, and the pH value from 6.00 to 8.00. With the anionic test solute (Cl–), the reaction
buffer was similar to its hydration buffer, but choline chloride was added to 100 mM, and the
pH value was lowered from 8.00 to 6.00. Using the intrinsic fluorescence of the kynurenine
residue, we confirmed that daptomycin binds quantitatively to the model membranes under
these experimental conditions (see Figure 3.1).
3.2.3 Spectrophotometric measurements
The permeation of thios into the liposomes was measured through reduction of entrapped
DTNB, which was measured by its absorption at 412 nm (ε = 13,400 M−1cm−1). DTNB-
loaded liposomes were diluted to a final concentration of 250 µM total lipids into the corre-
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sponding hydration buffer (Table 3.1) supplemented with 100 mM cysteine and 5 mM Ca++.
1 µM daptomycin was added to initiate the reaction.
3.2.4 Assessment of flow rate of different cations through daptomycin pores
To convert observed changes of pyranine fluorescence to permeation rates of cations, a cali-
bration curve for pyranine fluorescence as a function of pH was recorded. 200 mL of buffer
(5 mM MES, 5 mM tricine, 5 mM NaCl, 5 mM KCl, 250 mM sucrose, pH 6.00; the same
as used for the liposome interior when testing cation permeation) containing 2 µM pyranine
was titrated with 1 M NaOH, while measuring both the pyranine fluorescence intensity at 510
nm and the pH value after each successive addition. The measured curve was fitted with the
empirical polynomial function:
y = ax+bx1/2 + cx1/3 +dx1/4
The fitted function was then used as a calibration curve to convert the measured time-based
fluorescence traces to changes in the intra-liposomal proton concentration.
3.3 RESULTS
3.3.1 Effect of daptomycin on cation permeability
The permeability of liposomes for cations was measured using a coupled fluorescence assay
that is based on the pH-sensitive indicator pyranine, whose fluorescence increases with the pH
as its phenolic OH group dissociates between pH 6 and 8.5.37 The experimental rationale,
with potassium as an example, is illustrated in Figure 3.2. Dilution of the pyranine-loaded
liposomes into the final reaction buffer containing 100 mM KCl at pH 8 creates two opposite
ion concentration gradients across the liposome membrane: the K+ concentration is higher
outside, whereas the H+ concentration is higher inside (Figure 3.2A). Addition of the proton
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Figure 3.2 Schematic representation of the pyranine-based liposome permeabilization assay, us-
ing K+ ions as an example. Liposomes loaded with pyranine were diluted into the final reaction
buffer to create two opposite ion concentration gradients across the membrane (A). Application of
the protonophore CCCP alone will create a diffusion potential, which will prevent a major efflux
of protons (B). If daptomycin is added also and allows K+ ions to enter, both ion gradients can
dissipate, the pH in the liposome will rise, and pyranine fluorescence will increase (C).
ionophore CCCP alone to this system will cause little change to the pH within the liposomes,
since the efflux of protons will very soon be restricted by the ensuing diffusion potential (Figure
3.2B). The internal pH will change significantly only after addition of daptomycin, if, and only
if, daptomycin allows the influx of potassium ions. Both ion gradients will then dissipate, the
interior pH will rise, and pyranine will dissociate and fluoresce (Figure 3.2C).
The findings obtained using this assay with different cations are illustrated in Figure 3.3.
Panel A shows that the experiment works as expected with valinomycin, a potassium-specific
ionophore. With potassium, but not with sodium, the combination of valinomycin and CCCP
induces a rapid change that indicates swift dissipation of the proton gradient, facilitated by
exchange of protons and potassium ions across the membrane. CCCP alone does not induce
an appreciable change in fluorescence, while valinomycin alone shows a minor one; it may be
that valinomycin has a limited ability to translocate protons bound to it, as has been suggested
earlier.103
Figure 3.3B shows the same experiment with daptomycin instead of valinomycin. Again,
only the combination of daptomycin and CCCP induces a major change of fluorescence, while
either agent alone induces negligible changes in fluorescence. This indicates that daptomycin
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Figure 3.3 Time-based fluorescence traces of pyranine-loaded liposomes after exposure to differ-
ent test solutes and permeabilizing agents, which were added at t=0. The interior pH was 6 and
the exterior pH was 8. Test solutes added to the exterior buffer at 100 mM were KCl in B, and
otherwise as indicated; “hexa” in C and D is hexamethonium. After 300 seconds, the samples
were solubilized with Triton-X100, and the fluorescence monitored for another minute. The fluo-
rescence intensity observed after Triton solubilization was used to normalize each fluorescence
trace. A: Valinomycin (val., 0.5 µM) with CCCP (5 nM) permeabilizes liposomes for potassium, but
not sodium. B: Daptomycin (1 µM) plus CCCP (5 nM) also causes permeabilization for potassium
of membranes containing PG, but not cardiolipin. C: Permeabilization traces obtained with both
daptomycin and CCCP present, after subtraction of the traces obtained with CCCP only. D: Aver-
ages and standard deviations of fluorescence intensities after 300 seconds of incubation, for 3 or
4 independent experiments performed as in C (“chol.” is choline).
allows the influx of potassium ions. Also note that the rate of fluorescence change induced with
daptomycin/CCCP was significantly smaller than with valinomycin/CCCP, which indicates
that under the given experimental conditions the rate of fluorescence change was constrained
by daptomycin and not by CCCP. This latter conclusion is further supported by the experiments
shown in Figure 3.4 and 3.5.
Furthermore, when CCCP was added several minutes after daptomycin in order to allow
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Figure 3.4 Permeabilization of pyranine-loaded liposomes by gramicidin for sodium and magne-
sium, respectively. Gramicidin forms channels in membranes that are selective for monovalent
cations, including protons.67 In the presence of sodium (left panel), gramicidin alone suffices
to exchange sodium and protons across the liposome membrane. When carbonyl cyanide m-
chlorophenyl hydrazone (CCCP) is added, complete permeabilization is virtually instantaneous.
This indicates that, without CCCP, the rate of exchange was limited by proton transport, in keeping
with the low free proton concentration (1 µM inside the liposomes). The extent of permeabilization
is minor when sodium is replaced with magnesium.
lead time for daptomycin pore assembly before triggering ion gradient dissipation, the ensuing
fluorescence traces were very similar to those obtained with simultaneous application (data not
shown). This indicates that the rate of ion flux was not limited by the process of pore assembly,
but rather by the permeability of the already assembled pores.
When significantly higher concentrations of daptomycin were employed in combination
with CCCP, the rate of permeabilization increased, but there was also a notable increase in
the rate of fluorescence change in the absence of CCCP (data not shown). This agrees with
a previous study showing that, at higher concentrations, daptomycin destabilizes and induces
fusion of lipid bilayers.94 We therefore used a concentration of 1 µM throughout; this value is
similar to minimal inhibitory concentrations in susceptible bacteria.105
To further investigate the ion selectivity and functional size of the pores formed by dap-
tomycin, the same experimental conditions were used on a series of cations (Figure 3.3C).
The various metal ions, choline, and hexamethonium (N,N,N,N’,N’,N’-hexamethylhexane-
1,6-diaminium) were all used as their respective chloride salts and at the same molar con-
centrations. All metal ions produced a similar rate of fluorescence increase. Similar rates of
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Figure 3.5 Permeabilization for sodium ions with 2 µM daptomycin and 5, 7.5 or 10 nM CCCP
(traces with same amounts of CCCP only subtracted). The variation between curves is similar
to that also observed between repetitions that use the same amounts of CCCP (compare Figure
3.3D). Overall ion gradient dissipation is clearly limited by daptomycin, not CCCP.
permeabilization were also observed with lithium, rubidium, barium, and calcium (data not
shown); however, calcium is also a cofactor of daptomycin activity, which might conceivably
skew this measurement. Compared to the metal cations, choline and hexamethonium produced
significantly lower increases in fluorescence intensity (Figure 3.3C). Both are organic cations
and, in unhydrated form, are larger than the metal ions.
3.3.2 Effect of daptomycin on the permeability for anions
To determine whether daptomycin pores also allow the permeation of anions, the assay format
was varied slightly. Pyranine-loaded liposomes with high internal pH (8.00) were diluted into
a reaction buffer containing 100 mM choline chloride at low pH (6.00), creating H+ and Cl–
gradients that point the same way. Choline has been shown above to be only slowly transported
by daptomycin, whereas proton transport by CCCP is fast (compare Figure 3.3A); therefore, an
influx of chloride should mostly be compensated by a simultaneous influx of protons, lowering
the interior pH and causing the fluorescence to drop. This, however, was not observed; the
fluorescence intensity was not significantly affected by the presence of daptomycin, with or
without CCCP (Figure 3.6A). We conclude that daptomycin pores have no or low permeability
for chloride ions.
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Figure 3.6 Absence of liposome permeabilization toward chloride (A) and cysteine (B). A: Pyranine-
loaded liposomes with an interior pH of 6 were diluted 100 mM choline chloride, pH 8, and CCCP (5
nM) and daptomycin (1 µM) were added at t=0. Permeabilization for chloride should have resulted
in an accelerated dissipation of the pH gradient and concomitant drop in pyranine fluorescence. The
experiment shown is one of 4 independent ones and is representative. B: Time course of reduction
of DTNB entrapped in liposomes by 100 mM cysteine added to the outside, in the absence and
presence of daptomycin (1 µM). Reduction of DTNB results in an increase of the absorption at 412
nm. After the last reading at 10 minutes, samples were solubilized with Triton-X100, resulting in
immediate complete DTNB reduction. Error bars are standard deviations from three independent
experiments. Daptomycin does not increase in the permeation of cysteine into the liposomes.
3.3.3 Effect of daptomycin on the permeability for neutral solutes
DTNB (Ellman’s reagent) is useful for the detection of thiol groups in compounds such as
cysteine. Its disulfide bond is readily cleaved by thiols to produce 2-nitro-5-thiobenzoate,
which absorbs at 412 nm.63 We used it here to test the permeation of thiols across daptomycin
pores. In this experiment, DTNB-loaded liposomes were added to a solution containing 100
mM of thiol.
The experiment shown in Figure 3.6B depicts the findings obtained with cysteine. Absorp-
tion was measured every 2 min over a period of 10 min, which showed no significant change
until 0.1% Triton X-100 was added. Addition of 1 µM daptomycin did not accelerate the re-
duction of DTNB (indeed it seemed to slightly delay it), indicating that the daptomycin pore
allows no or only slow passage of cysteine across the membrane.
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Cysteine has a neutral net charge, but it is not uncharged. Two uncharged thiols, dithiothre-
itol (DTT) and 2-mercaptoethanol, were also tested. These molecules, however, were found to
swiftly enter the liposomes and reduce DTNB even at lower concentrations and in the absence
of daptomycin, so that no conclusion could be reached as to their ability to be transported by
daptomycin pores.
These findings do not allow us to clearly assess the ability of daptomycin to transport
neutral solutes; cysteine transport may be limited either by lack of a positive charge or by its
molecular size.
3.3.4 Estimation of the rate of ion flow across daptomycin pores
As illustrated in Figure 3.2, each proton that is to leave the liposome needs to be replaced by
one (alkali metals and choline) or one half (magnesium and hexamethonium) cation that enters
through a daptomycin pore. Therefore, a given decrease in the total (buffered and unbuffered)
proton concentration corresponds to a proportional increase in the concentration of the test
cation, and it is thus possible to estimate the rate of permeation through daptomycin pores
from the rate of fluorescence change.
The relationship between pyranine fluorescence intensity and total proton concentration
was determined empirically using NAOH to titrate pyranine-containing cation hydration buffer.
The titration curve was mathematically fitted with an empirical polynomial function (Figure
3.7A), which was then used to convert the previously acquired fluorescence traces to changes
of intravesicular cation concentrations (Figure 3.7B). The rates of change are highest for the
alkali metal ions and lowest for magnesium and hexamethonium.
In Figure 3.7C, the rate of sodium transport during the first minute was approximated using
a single-exponential fit. The parameters of this fit indicate an initial transport rate of 22 µM
per second. To estimate the number of ions actually transported, we need to consider that the
experiment observes the change in ion concentration only within the intraliposomal volume.
Liposomes with 100 nm diameter and at a total lipid concentration of 250 µM should enclose
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Figure 3.7 Conversion of observed pyranine fluorescence changes to cation flow rates. A calibra-
tion curve relating total (buffered and unbuffered) proton concentration to pyranine fluorescence
intensity was obtained by titrating a solution matching the liposome interior with NaOH (A). A poly-
nomial function was fitted to the measured values. In panel B, the polynomial function obtained
in A was applied to the raw fluorescence traces shown in Figure 3C in order to transform them to
ion fluxes. The flow rates for hexamethonium and Mg++ were then divided by 2, as each of these
cations is exchanged for 2 protons. In C, an exponential function was fitted to the transport curve
for sodium in order to estimate the initial transport rate (see text for further details).
approximately 0.08% of the total volume. Therefore, an apparent ion transport rate of 22
µM/s converts to a liposomal entry of only 18 nM/s from the bulk volume. The daptomycin
concentration is 1 µM; if all daptomycin molecules are indeed incorporated into functional
pores, and each pore is an oligomer that consists of 7 or 8 subunits,143 the average transport
rate of each pore is approximately 0.12 sodium ions per second. While this is only a rough
estimate, it is clear that ion transport by daptomycin is many orders of magnitude slower than
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those of typical cellular ion channels or of gramicidin, which transports upward of 106 ions per
second under similar conditions67 (compare also Figure 3.4).
3.4 DISCUSSION
In previous experiments, it was shown that daptomycin forms oligomers on the membranes of
liposomes consisting of PC and PG, as well as on bacterial cells.142, 144 These oligomers were
subsequently shown to contain approximately 7 subunits each143 and to be involved in the bac-
tericidal action of daptomycin. We recently proposed a revised and more detailed model, in
which the oligomer comprises eight subunits, with four each in the inner and the outer mem-
brane leaflet (see Chapter 4). Earlier studies had established that daptomycin depolarizes the
cell membranes of susceptible bacteria.3, 5, 184 From the closely parallel observations obtained
with the liposome model and with bacterial cells regarding oligomer formation, the question
arose whether the functional daptomycin lesion could also be observed and characterized in
the liposome model.
The findings reported here show that this is indeed the case. Daptomycin was found to
permeabilize the liposome membranes in a cation-selective fashion. The rate of permeation was
virtually the same for all alkali metal ions. It was approximately twice lower for magnesium,
and lower again for the organic cations choline and hexamethonium, indicating that the pore
also discriminates between different cations, most likely according to size.
When comparing the bare ions, without hydration shells, the two organic cations are much
larger than all of the metal ions; both choline and hexamothonium contain tetramethylammo-
nium as a moiety, which has an unhydrated diameter of 5.7 Å. In contrast, when we take the hy-
dration shells into account, magnesium at 8.6 Å exceeds the alkali metals and the organic ions,
which are all close to 7 Å (all ionic diameters according to210). In membrane nanofiltration
experiments,201 sodium and potassium have been found to be more permeant than magnesium
and calcium, and it was proposed that nanopore permeation involved the partial shedding of
hydration shells. Partial dehydration may also be involved in ion permeation across the dapto-
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mycin pore. The organic cations bind their hydration shells most weakly;8 nevertheless, they
are less readily transported than the alkali metal ions, which suggests that daptomycin prefers
ions with an effective radius below that of unhydrated choline or hexamethonium. Chloride,
in both hydrated and unhydrated forms, is very similar in diameter to potassium; therefore, its
exclusion is apparently not caused by size but may be due to electrostatic repulsion between it
and one of the several acidic residues on the daptomycin molecule. It seems likely that the pore
is also permeable for protons; however, due to the very low free (as opposed to buffered) proton
concentration at near neutral pH, this would not result in a rapid dissipation of transmembrane
proton gradients and therefore would not be detected in our assay.
The observations reported here agree rather well with previous reports on the permeabiliza-
tion of bacterial cells. Daptomycin depolarizes Bacillus cells and disrupts their uptake of amino
acids, which is mostly driven by cation cotransport, but does not induce leakage of already ac-
cumulated amino acids.5 The major cations that control the membrane potential are potassium
and sodium. In an intact cell, the permeability is higher for potassium than for sodium, which
creates a negative-inside membrane potential. Changing the permeability balance in favor of
sodium will depolarize the membrane. This would occur with either sodium-selective channels
or with non-selective pores such as those formed by daptomycin, which indeed reproducibly
induces depolarization. Interestingly, one experimental study reported a short-lived yet distinct
transient hyperpolarization, followed by depolarization.124 The extracellular medium used in
that study was low in sodium; in this situation, permeabilization for both sodium and potassium
might produce a transient dominance of the strongly negative potassium equilibrium potential,
which would then collapse as the cytosol becomes depleted of potassium through continued
leakage.
A quantitative estimation of the rate of ion transport for a single daptomycin pore indicated
that this rate is several orders of magnitude lower than that of gramicidin, another peptide
antibiotic that permeabilizes membranes for cations. It must be noted that the transport rate
obtained here for daptomycin is an average value; while it might indeed apply to each of the
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functional pores in the ensemble, it is also possible that only a small fraction of all daptomycin
oligomers form functional pores, with correspondingly greater permeability, or that the pores
alternate between closed and open states, with the latter only prevailing during a small fraction
of the time. While the conductivity properties of the individual daptomycin pore must be deter-
mined in future experiments, the low average conductivity, compared with a dedicated channel
former such as gramicidin, might suggest that pore-formation may be only one of several as-
pects of daptomycin’s bactericidal action. It should, however, be noted that no additional action
mode has been biochemically substantiated.169 Moreover, liposome permeabilization is read-
ily observed with daptomycin concentrations equivalent to typical MIC values,184 even though
the ratio of daptomycin molecules to membrane lipids is lower in a liposome experiment than
in a bacterial culture freshly inoculated for MIC measurement; this supports the notion that
membrane permeabilization is relevant to antibacterial activity.
In sum, our study shows that a very simple artificial membrane model suffices to elicit
and characterize the pore-forming activity of daptomycin. The only lipid specifically required
for pore formation in our model is PG. A key role for PG in vivo is consistent with several
studies on the causation of bacterial resistance to daptomycin.12, 72, 79 The availability of a
simple yet sufficient liposome model for daptomycin pore formation should be useful in further
characterizing the structure and action mode of daptomycin, as well as the molecular basis of
bacterial resistance.
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Chapter 4
Cardiolipin Prevents Membrane Translocation and Permeabilization
by Daptomycin
4.1 INTRODUCTION
The antibacterial action mode of daptomycin (Figure 4.1) is not yet fully understood and may
be multifaceted. Membrane permeabilization and interference with cell division have been
demonstrated, whereas inhibition of cell wall synthesis remains somewhat contentious.105
Membrane permeabilization can be observed in model liposomes and involves the formation
of an oligomeric and cation- and size-selective pore, as detailed in the preceding chapter. Oli-
gomerization and pore formation require phosphatidylglycerol (PG),12 which is abundant in
bacterial cell membranes but not in mammalian ones; this presumably contributes to the selec-
tivity of the drug for bacteria.12, 78, 79, 137
The results presented in this chapter have been published in: “Cardiolipin Prevents Membrane Translocation
and Permeabilization by Daptomycin”, by TianHua Zhang, Jawad K. TianHua Zhang, Nasim Tishbi, Jennifer
Herskowitz, Rachel L. Victor, Jared Silverman, Stephanie Uwumarenogie, Scott D. Taylor, Michael Palmer, and
Evan Mintzer (2014), J. Biol. Chem. 289: 11584-91
Authors’ contributions: The experiments depicted in Figure 4.5 and 4.6 were performed by N. Tishbi, J. Her-
skowitz, R.L. Victor, and E. Mintzer. The synthesis and purification of perylene-daptomycin was performed by
S. Taylor. All other experiments were done by the thesis author.
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Figure 4.1 Structure of daptomycin. In NBD-daptomycin, the free amino group of ornithine is
modified with NBD. In perylene-daptomycin, the N-terminally attached decanoyl residue is replaced
by perylene-butanoic acid.142 Kynurenine has intrinsic fluorescence that can be used for FRET
experiments in conjunction with NBD.144
Since its approval for clinical use in 2003, daptomycin has assumed a major role in the treat-
ment of infections with Gram-positive pathogens. Although the overall resistance situation is
currently still favorable, resistant strains of Staphylococcus aureus and Enterococcus species
occur. Genomic analysis of resistant strains indicate that resistance may involve changes in the
lipid composition of the bacterial cell membrane. Such changes include the reduced synthesis
of PG79 and the increased conversion of PG to lysyl-phosphatidylglycerol (lysyl-PG).72 Be-
cause lysyl-PG is positively charged, it likely detracts from the calcium-mediated membrane
binding of daptomycin, which would resemble its known inhibitory effect on cationic antimi-
crobial peptides.
Another set of mutations implicates cardiolipin. Mutations that enhance cardiolipin syn-
thase activity44 were found in resistant Enterococcus strains,158 although replacement of the
wild-type synthase with a mutant gene into a wild-type Enterococcus faecalis strain did not
detectably change the susceptibility to daptomycin.207 Quantitative data on cardiolipin mem-
brane levels in daptomycin-resistant Enterococcus strains are not available; therefore, whether
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or not changes in cardiolipin content can increase the daptomycin resistance in vivo remains
to be elucidated. Here, we examined the question whether or not cardiolipin can in principle
affect the susceptibility of membranes to daptomycin. We found that cardiolipin may indeed
protect lipid membranes from permeabilization. The inhibitory mechanism of cardiolipin is
novel and surprising, and it provides further insight into the mechanism of daptomycin pore
formation.
4.2 MATERIALS AND METHODS
4.2.1 Preparation of liposomes (LUV) for fluorescence experiments
The procedures for preparing the large unilamellar vesicles have been described in a preceding
chapter (see Section 2.2.2). Lipid tetraoleyl-cardiolipin (TOCL)was also obtained from Avanti
Polar Lipids (Alabaster, AL) and used as received. All lipids were mixed at the molar ratios in-
dicated under “Results” (Section 4.3). All experiments involving these liposomes were carried
out at 30 °C.
4.2.2 Preparation of liposomes (LUV) for ITC experiments
LUV were prepared using the freeze-thaw and extrusion method as described in Chapter 2.
Lipid films were prepared by mixing appropriate volumes of pure DOPC, DOPG, and TOCL
(Avanti) from stock solutions in chloroform and evaporating the solvent under a stream of
nitrogen. The resulting films were hydrated in HBS (10 mM Hepes, 100 mM NaCl, 1 mM
CaCl2, pH 7.4) to a final total lipid concentration of 5 mM.
4.2.3 Measurement of membrane permeabilization with pyranine-loaded liposomes
This procedure was carried out exactly as described in the preceding chapter (Section 3.2.2).
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4.2.4 Measurements of perylene excimer fluorescence
Perylene-daptomycin was prepared as described before.142 The compound was added to LUV
at 2 µM. Calcium was added to 5 mM, the samples were incubated for 5 min, and the fluores-
cence emission was recorded with excitation at 430 nm.
4.2.5 Isothermal calorimetry
Energetics of daptomycin binding to model membranes was investigated by high sensitivity
isothermal titration calorimetry using a MicroCal VP-ITC instrument (GE Healthcare) as de-
scribed in Section 2.2.3. Briefly, the sample cell (∼1.4 mL) was filled with 23 µM daptomycin
prepared in HBS containing 1 mM calcium, and the reference cell was filled with identical
buffer. The 250-µL syringe was loaded with 5 mM total lipid LUV suspension. Daptomycin
solutions and lipid suspensions were degassed with stirring under vacuum for 20 min prior to
each titration. After system equilibration and a preliminary 1 µL injection that was omitted
from data analysis, 2.5 µL aliquots were injected into the sample cell at 6 min intervals. Data
were collected by the MicroCal-customized Origin software. Baselines were normalized using
the software Nitpic,99 and the results were analyzed with the Origin “one binding site” model.
4.2.6 Langmuir monolayers
The ability of daptomycin to penetrate lipid monolayers was examined using a Langmuir sur-
face balance and custom-built mini-trough from KSV-Nima (Biolin Scientific, Espoo, Finland).
The aqueous subphase was HBS with 1 mM calcium, prepared with water purified through a
Milli-Q system (Millipore, Molsheim, France). Lipid solutions were prepared by dissolving
DOPC, DOPG, and TOCL in spectroscopy-grade chloroform to concentrations of ∼1 mg/mL.
The trough was filled with buffer, and the surface was cleaned by aspirating. Small aliquots of
lipid solution were applied to the surface using a Hamilton digital syringe (Reno, NV) until an
initial surface pressure of 20 mN/m was obtained. After allowing 10 min for solvent evapo-
ration and monolayer equilibration, 50 µL of 1 mM daptomycin, prepared in identical buffer,
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were injected into the stirred subphase through a side port to avoid puncturing the monolayer.
Daptomycin insertion into the lipid monolayer was monitored over time and detected by sur-
face pressure increase at constant area. Each experiment was performed at least in triplicate.
4.2.7 Determination of daptomycin oligomer subunit stoichiometry by FRET
Nitrobenzoxadiazole-daptomycin (NBD-daptomycin) was prepared as described previously.144
Fluorescence experiments and data analysis, too, were performed exactly as described be-
fore,143 except that the lipid composition of the liposomes was varied as indicated in Section
4.3. Briefly, the stoichiometry is inferred from the extent of FRET between native daptomycin
and NBD-daptomycin within hybrid oligomers, using the assumption of random co-assembly
and experimental correction for FRET between neighbouring oligomers.
4.2.8 Dithionite quenching of NBD fluorescence
For the experiment shown in Figure 4.8A, NBD-phosphatidylethanolamine (NBD-PE) was
obtained from Avanti and incorporated at 0.5% mol/mol into LUV that otherwise consisted
of equal fractions of PC and PG. The liposomes were diluted into HBS supplemented with
25 mM calcium. We found it necessary to raise the concentration this high from the usual
value of 5 mM to induce reaction between dithionite and liposomes containing PG; we assume
that calcium alleviates the electrostatic repulsion between PG and dithionite. Daptomycin was
added to 1 µM where indicated, and the samples were incubated for 5 min before starting the
fluorescence measurement (excitation wavelength, 465 nm; emission wavelength, 530 nm).
After 1 min, dithionite was added (final concentration 10 mM), and the measurement was
continued for another 5 min before the addition of Triton X-100 to solubilize the liposomes.
The experiments illustrated in Figure 4.8B were performed analogously, except that NBD-
PE was omitted from the liposomes, and daptomycin was replaced with a mixture of NBD-
daptomycin and native daptomycin (molar ratio 1:2; total final concentration 1 µM). The in-
clusion of native daptomycin served to reduce NBD self-quenching.
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Figure 4.2 Permeabilization by daptomycin of liposomes composed of PC and PG (A) and PC, PG,
and CL (B). The pH-sensitive fluorophore pyranine was entrapped in liposomes. The increase in its
fluorescence by the efflux of protons was mediated by carbonyl cyanide m-chlorophenylhydrazone
(CCCP), in exchange for potassium influx mediated by valinomycin (green) or daptomycin (red).
Valinomycin is active on both membranes (but acts faster on the ones containing CL), whereas
daptomycin permeabilizes only the membranes devoid of CL. The fluorescence intensity is scaled
to that observed after solubilization with Triton X-100, which equals 100 units.
4.3 RESULTS
4.3.1 Cardiolipin Inhibits Membrane Permeabilization by Daptomycin
In the preceding chapter, we showed that daptomycin forms cation-selective pores of discrete
size in liposomes composed of PC and PG. As shown in Figure 4.2, the addition of as little as
10% cardiolipin completely inhibits this pore formation.
In previous studies, we have shown that membrane permeabilization by daptomycin occurs
in several successive stages, namely, monomer binding, oligomerization, and conversion of the
oligomer to a functional pore.142–144 The following experiments were carried out to determine
which of these stages is subject to inhibition by cardiolipin.
4.3.2 Binding and oligomerization of daptomycin on membranes containing cardiolipin
The binding of daptomycin to lipid membranes correlates with a strong increase in the intrinsic
fluorescence of its kynurenine residue.107 Binding also requires calcium, and the calcium con-
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Figure 4.3 Fluorescence of perylene-daptomycin on liposomes containing PC alone or in various
combinations with PG (mole fraction 30%)and CL (mole fraction 10%). A, on PC membranes as
well as on PC/CL membranes, the spectrum is characteristic of the perylene monomer, indicating
that oligomer formation does not occur. PC/PG membranes with or without 10% CL show a dimin-
ished monomer peak and a broad, overlapping excimer peak indicative of oligomer formation.142
The extent of excimer formation is slightly lower in the sample with CL. B, the ratio of emissions
at 560 and 445 nm can be used to compare the extent of excimer formation. This ratio is shown
here as a function of the CL mole fraction (0–70%). PG was constant at 30%, and the balance was
made up by PC.
centration required to induce the half-maximal extent of this fluorescence increase ([Ca]50) can
be used to compare the affinity of daptomycin for membranes differing in lipid composition.
The [Ca]50 is ∼12 mM calcium with pure DMPC membranes, 0.2 mM with DMPC/DMPG
membranes (1:1), and 2 mM with DMPC/TOCL membranes. Thus, CL binds daptomycin
more avidly than PC but less avidly than PG. When CL is added to PC and PG, the [Ca]50
remains close to 0.2 mM, which suggests that on such membranes, daptomycin interacts with
PG rather than CL (data not shown).
Oligomerization of membrane-bound daptomycin can be observed through excimer forma-
tion of a perylene-labeled daptomycin derivative.142 Figure 4.3A shows the fluorescence of
perylene-daptomycin on membranes containing PC, PG, and CL in various combinations. As
reported before,142 the emission spectrum observed on PC membranes is typical of perylene
monomers, indicating the absence of daptomycin oligomer formation. On membranes con-
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sisting of PC and PG, monomer intensity is reduced, and an overlapping, broad-based peak
excimer peak centered around 520 nm appears, indicating daptomycin oligomer formation on
these membranes.
The spectrum obtained with membranes containing PC and CL, but no PG, closely re-
sembles the one from pure PC liposomes. Therefore, unlike PG, cardiolipin does not induce
oligomerization of daptomycin. In contrast, membranes that contain both PG and CL do induce
formation of excimers, and hence of daptomycin oligomers.
The extent of excimer formation can be compared using the ratio of the emission at 560 nm,
where monomer fluorescence is negligible, with that at 455 nm, where monomer fluorescence
is dominant. In Figure 4.3B, this ratio is shown as a function of CL molar fraction in the
membrane. The extent of excimer formation drops noticeably from 0 to 10% CL and then
increases slightly again as more CL is added. The potential significance of this finding is
discussed below.
Another method for observing daptomycin oligomerization is the use of FRET between
the kynurenine residue of the unlabeled molecule and the fluorescent label NBD attached to
the ornithine side chain of a second daptomycin molecule; the NBD derivative retains full
antibiotic activity.144 This method has also been used to estimate the number of subunits in
a single daptomycin oligomer to 6–7.143 In those previous experiments, PC/PG membranes
where used, which allow the formation of functional pores (Figure 4.2A). Because the addition
of CL prevents pore formation, we considered that the oligomers that form in the presence of
CL might be structurally different and contain a different number of subunits.
The experimental approach used in this experiment is fully explained in a previous study.143
Briefly, native daptomycin and NBD-daptomycin are mixed in various proportions and then
applied to liposome membranes. Interpretation is based on the assumptions of 1) oligomer
stability on the time scale of the experiment, 2) random co-oligomerization, and 3) maximally
effective FRET between the subunits of the same oligomer. Then, using experimental correc-
tions for FRET between molecules that are part of separate oligomers, the number of subunits
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Figure 4.4 Estimation of subunit stoichiometry of the daptomycin oligomer by FRET between native
daptomycin (donor) and NBD-daptomycin (acceptor). A, native daptomycin (3 µM final) and NBD-
daptomycin (0.5 µM final) were added to liposomes containing PC (40%), PG(50%), and CL (10%),
either sequentially, with incubation for 5 min between additions, or premixed. Emission spectra
were acquired 5 and 15 min after the final addition. The peak at 450 nm represents the kynurenine
emission of native daptomycin, whereas the peak at 540 nm is due to NBD. The donor emission of
the sequential sample is higher than that of the premixed sample, which is due to the formation of
segregated, stable oligomers. It is lower than that of donor alone, which is due to FRET between
those segregated oligomers. The emission of the sequential sample remains almost the same
after 15 min, which shows that the oligomers are stable on the time scale of the experiment. AU,
arbitrary units. B, the two species were mixed before application to liposomes containing PG (50%),
CL (0–20%, as indicated), and PC (balance to 100%) to induce the formation of hybrid oligomers.
The corrected relative donor fluorescence (Fr) was obtained as described in reference.143 The
colored lines represent theoretical Fr functions for the indicated numbers of subunits; each data
point represents the means±SD of 3 or 4 repeated experiments.
can be calculated from the reduction of donor fluorescence intensity that is observed in the
presence of a given amount of acceptor.
Figure 4.4 shows that, indeed, the presence of cardiolipin changes the subunit stoichiome-
try. With cardiolipin, there were close to four subunits, whereas without CL, the number was
close to seven, which is similar to the previously reported value.143 These observations will be
further discussed below.
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Figure 4.5 Surface pressure change of lipid monolayers consisting of CL (% mol/mol as indicated)
and equal fractions of PC and PG, in response to injection of daptomycin into the subphase. A,
time profiles; daptomycin was injected at t = 0 and at an initial surface pressure of 20 mN/m. B,
changes in surface pressure derived from the data in panel A. Results were reproducible to within
5% (n=3–5). Each data point represents the means±SD of 3–5 repeated experiments. C, surface
pressure change as a function of initial pressure on PC/PG membranes without CL. The surface
pressure increment drops linearly with the starting pressure. The slope of the regression line is
-0.885; at a slope of -1, the final surface pressure would be entirely independent of the starting
pressure.
4.3.3 Interaction of daptomycin with membranes containing CL by surface pressure and
isothermal calorimetry (ITC)
To better understand the effect of CL on the membrane interaction of daptomycin, we studied
a similar model system with Langmuir monolayers and with ITC. The insertion of daptomycin
into PC/PG lipid monolayers can be observed as an increase in surface pressure. The addition
of CL to this lipid mixture up to a molar fraction of 10% substantially enhances this response
(Figure 4.5, A and B). This increase in the surface pressure differential indicates a deeper
and/or more stable insertion of daptomycin molecules into monolayers containing CL. The
surface pressure differential decreases again when CL is added to molar fractions of 20% or
greater.
ITC was performed with LUV, which were added to a solution of daptomycin and calcium.
Figure 4.6 shows that, relative to liposomes containing PC and PG only, the addition of CL up
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Figure 4.6 ITC experiments on daptomycin binding to PC/PG membranes with or without CL. A,
representative raw traces. Each peak is caused by the injection of 2.5 µ l of liposome suspension
(see Section 4.2.5 for experimental details). B, integrals (data points) and single-site model fit
curves for the traces shown in A. C, energies of interaction between daptomycin and liposome
membranes (mole fraction of CL as indicated, balance of equal parts of PC and PG) obtained from
a series of isothermal titrations (n=2 or 3 at each lipid composition). Each data point represents the
means±SD of 3 or 4 repeated experiments.
to a molar fraction of 10% raised the enthalpy released by daptomycin binding significantly.
This increase in negative enthalpy indicates a greater number of favorable molecular interac-
tions between daptomycin and the lipid molecules of the membrane, which is consistent with
the deeper membrane insertion of daptomycin molecules inferred from the surface pressure
experiments.
The increase in negative enthalpy was accompanied by a decrease in entropy, as obtained
by fitting a single-site binding model to the raw data. At a molar fraction of 20% or more CL,
the changes to both the enthalpy and the entropy were partially reversible.
It may be noted that the response to changes in CL molar fraction was similar in three
different assays, namely surface pressure, ITC, and perylene excimer fluorescence, which sug-
gests that these assays reflect the same underlying effect of CL on the membrane interaction
of daptomycin. In all three assays, the maximum signal was observed at a CL mole fraction
of 10%, whereas higher mole fractions caused a partial reversal. We currently have no ex-
perimental basis on which to propose an explanation for this reversal. It may be noted that
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Figure 4.7 Hypothetical model of daptomycin membrane insertion, pore formation, and pore struc-
ture. A daptomycin tetramer forms in the outer membrane leaflet (A). Its insertion into the head
group layer is limited by the distension and creation of voids in the acyl chain layer (B); this is un-
favorable in terms of enthalpy and increases disorder (entropy). If CL is present, it provides extra
bulk in the acyl chain layer, which stabilizes this situation and thus allows for deeper penetration of
daptomycin. If CL is not present (C), head group distension and voids in the acyl layer may alter-
natively cause the outer leaflet to cave in, forming a half-toroidal structure. A tetramer as shown in
C may flip to the other leaflet and then combine with a second tetramer in the outer leaflet, which
gives an octameric pore (D).
molar fractions of CL higher than 10% are not common in bacterial membranes, so that this
observation may not be relevant to the interaction of CL and daptomycin in vivo.
4.3.4 Cardiolipin inhibits membrane translocation of daptomycin
One question that had not been addressed in our previous studies is how daptomycin dis-
tributes between the two leaflets of the target membrane. The observation that cardiolipin
both prevented pore formation and reduced the number of oligomer subunits by approximately
half suggested the possibility that a functional pore might comprise subunits in both leaflets,
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Figure 4.8 Distribution of daptomycin across inner and outer leaflets, examined with NBD fluores-
cence quenching using dithionite. A: Control. Dithionite (10mM) reduces only 50% of NBD-PE
(0.5% in PC/PG membranes), both in the absence and in the presence of daptomycin. There-
fore, dithionite continues to be excluded from membranes in the presence of daptomycin pores.
A. U., arbitrary units. B: In PC/PG membranes containing 10 or 20 % CL, most of the NBD-
daptomycin (NBD-dap) is reduced by dithionite instantly, indicating that it is confined to the outer
leaflet. In contrast, in PC/PG membranes containing no CL, immediate reduction affects only 50%
of NBD-daptomycin, whereas the remainder is reduced at a slower pace, presumably rate-limited
by redistribution from the inner to the outer leaflet.
whereas the nonfunctional oligomers that form in the presence of cardiolipin might be con-
fined to the outer membrane leaflet only (Figure 4.7). This hypothesis was tested using the
fluorescence of NBD-daptomycin and its sensitivity to quenching with dithionite.
NBD is instantly reduced, and its fluorescence is abolished, by dithionite. Because dithion-
ite is membrane-impermeant, this reaction can be used in liposome models to detect the acces-
sibility of membrane-associated molecules from the outside.128 A potential complication that
arises here, however, is that daptomycin pores might allow dithionite to reach the liposome
interior and reduce NBD-daptomycin also bound to the inner leaflet. Therefore, in a control
experiment, a small amount of NBD-PE was incorporated into PC/PG liposomes, and its reduc-
tion by dithionite was monitored both with and without daptomycin. In both cases, the extent
of reduction is close to 50%, which is consistent with a reduction of NBD-PE in the outer
leaflet only (Figure 4.8A). Thus, in keeping with the observed cation selectivity of the dapto-
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mycin pore that was discussed in the preceding chapter, dithionite does not appreciably enter
the liposomes on the time scale of the experiment. Dithionite was also excluded by liposomes
containing CL in addition to PC and PG, with or without daptomycin (data not shown).
Figure 4.8B depicts the results obtained with NBD-daptomycin; no NBD-PE was present in
these experiments. When NBD-daptomycin was bound to membranes containing PC, PG, and
either 10% or 20% CL, almost all NBD fluorescence was immediately quenched. In contrast,
the extent of immediate quenching was only about 50% in membranes that contained PC and
PG but no CL. The remainder of the fluorescence decayed more slowly with a half-life of∼60–
90 s, which is presumably due to the redistribution of daptomycin from the inner to the outer
leaflet. These findings support the notion that daptomycin is able to distribute symmetrically
and reversibly between both membrane leaflets in PC/PG membranes, but unable to translocate
across membranes containing 10 or 20% CL.
4.4 DISCUSSION
In this study, we have shown that cardiolipin inhibits the pore-forming activity of daptomycin
in a liposome model. This study was prompted by genetic studies on daptomycin resistance,
which suggest that bacteria may become more resistant to daptomycin by increasing the con-
tent of cardiolipin in their cell membranes. We found that inclusion of 10% CL in model
membranes was sufficient to effectively suppress membrane translocation and pore formation
in liposomes. This fractional amount of CL is at the upper end of the range reported for bacte-
rial cell membranes,36, 50, 134 which suggests that this mechanism may be relevant for bacterial
resistance to daptomycin. Formation of daptomycin pores in bacterial cell membranes, as de-
tected by membrane depolarization, is well documented.3, 124, 184 It seems possible that an
increased cardiolipin content would inhibit pore formation in vivo; however, this has yet to be
experimentally examined. Daptomycin may also damage bacteria by more than one mecha-
nism. If so, inhibition of pore formation may not suffice to prevent bactericidal action, and
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additional resistance mechanisms would then be required to counter the other antibacterial ac-
tion modes of the drug.
Whether or not the effect of CL observed in vitro has a role in bacterial resistance, the
findings of our study do provide significant new insight into the mechanism of daptomycin
action. Firstly, they show that oligomers can form in the outer leaflet alone. However, these
oligomers do not form functional pores, and they do not reach the full number of subunits;
instead, they contain only four subunits. Pore formation correlates with daptomycin reaching
the inner membrane leaflet, and with an increase in the apparent subunit stoichiometry to 6–7.
To account for the collective findings, we propose a working model of pore formation
that comprises the following steps (Figure 4.7): 1) calcium-mediated binding of monomeric
daptomycin to PG in the outer leaflet of the target membrane; 2) formation of a tetramer from
four bound monomers (this step occurs in the outer leaflet and is preserved in membranes that
contain cardiolipin); 3) translocation of tetramers from the outer leaflet to the inner leaflet
(this step is disrupted on membranes containing CL); and 4) alignment of two tetramers in the
opposite leaflets to form an octameric functional pore.
In such an octamer, half of the subunits are located in the outer leaflet and hence subject to
reduction by dithionite right away. The observation that the remainder of the NBD fluorescence
is subject to protracted but ultimately complete reduction indicates that the translocation from
the outer to the inner leaflet is reversible. The reverse translocation might conceivably involve
the dissociation of octamers into tetramers. However, we could find no evidence of such a
dissociation in preliminary experiments, and we therefore favor the view that translocation
comes about through the trading of places between individual subunits within an intact octamer.
Although this model accounts for most of the available evidence without contortions, the
postulated octamer obviously is at odds with the subunit stoichiometry (n) of 6–7 that was
experimentally obtained with PC/PG membranes here and earlier.143 Two effects might ac-
count for this discrepancy. Firstly, it is possible that not all tetramers assemble into octamers.
In that case, the experimentally determined number would reflect an average of tetramers and
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octamers, weighted for abundance. However, because we could not detect dissociation of oc-
tamers into tetramers, it seems likely that the number of free tetramers is low at equilibrium.
Secondly, as was pointed out in our previous study,143 the stoichiometry obtained from
FRET experiments may underestimate the true value. The efficiency of FRET is limited by
the Förster distance, which was estimated to 2.7 nm for the couple of donor and acceptor la-
bels used here (kynurenine in unlabeled daptomycin and NBD-daptomycin, respectively). The
distance between subunits that belong to the same oligomer, yet reside in opposite membrane
leaflets, might approach or even exceed this value, which would significantly diminish FRET.
Because our analysis assumes FRET to be maximally effective between any two positions
within the same oligomer,143 a less than maximal FRET efficiency will cause the calculated
number of subunits to underestimate the true value. Based on the currently available evidence,
we consider this the most likely explanation.
If we assume the above model to be correct, the question arises exactly how cardiolipin may
inhibit membrane translocation of daptomycin tetramers. This inhibitory effect was accompa-
nied by several other changes. The slight drop of perylene excimer fluorescence (Figure 4.2B)
may correspond to the fraction of excimers that form between perylene-daptomycin molecules
in two opposite tetramers that are part of the same octamer, whereas the remaining excimer
fluorescence arises from proximity within single tetramers. In liposomes, CL effected a no-
table increase in daptomycin binding enthalpy, which suggests an increase in the number of
favorable molecular contacts.1 In lipid monolayers, CL caused a greater increase in surface
pressure in response to a given quantity of daptomycin. This suggests a deeper insertion of
daptomycin into membranes containing moderate amounts of CL, which should increase the
number of molecular contacts between daptomycin and the surrounding lipids, and therefore
agrees with the findings from the ITC experiments.
A similar inhibitory effect of CL on membrane pore formation has previously been ob-
served with the antimicrobial peptide magainin, and together with related findings has been
interpreted in terms of lipid curvature strain.125 According to this explanation, the peptide
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claims space in the head group layer of the membrane. CL and other “cone-shaped” lipid
species that provide more bulk in the hydrophobic acyl chain layer than in the head group layer
accommodate the peptide, whereas lipids with larger head groups compete with it for space,
promoting distension and bending of the head group layer, which leads to the formation of a
toroidal pore.
The mechanism proposed for magainin may also underlie the effect of CL on daptomycin
(Figure 4.7). Such a model might lead one to expect that, because of the greater competition
for space in the head group layer of monolayers without CL, daptomycin insertion into such
monolayers should raise the surface pressure to a greater extent than without CL, which is
the opposite of what we observed (Figure 4.5). Possibly, the unstable situation illustrated in
Figure 4.7B may relax by transitioning either toward the toroidal defect (Figure 4.7, C and D)
or toward a less deeply inserted configuration, in which the bulk of the peptide remains outside
of the lipid membrane and does not add lateral pressure to it (Figure 4.7A). In any event, an
improved accommodation of daptomycin within CL-containing membranes would agree with
the increase in negative enthalpy reported here. In this context, it is worth noting that CL
is believed to be enriched in localized domains in bacterial cell membranes.98 This might
account for the inhomogeneous distribution of daptomycin on cell surfaces;164 the correlation
has, however, not been established.
A tighter interaction between daptomycin and membrane lipids might also account for
the decrease in entropy that was observed concomitantly with increases in negative enthalpy.
However, one should keep in mind that the entropy values were obtained through the use of a
single-site binding model, and although this model is able to numerically fit the ITC titration
curves rather well, we must not forget that daptomycin not only binds as a monomer but sub-
sequently also forms oligomers, so that any model that assumes a one-step interaction can only
be considered an approximation. Caution is therefore required with respect to interpreting the
calculated entropy.
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In sum, we have obtained evidence that supports a novel structural model of the daptomycin
pore and suggests a possible mechanism of bacterial resistance to daptomycin. We presently
have no way to further corroborate this hypothetical model. Nevertheless, it is interesting
to note that many cation channels and pores have tetradic symmetry. Intriguingly, with the
Pseudomonas lipopeptide tolaasin I, whose structure is not closely related to daptomycin, the
very same kind of octameric symmetry spanning both leaflets has been obtained from in silico
studies.92 We therefore feel that this structural model deserves consideration in future studies.
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Chapter 5
Summary and future work
5.1 SUMMARY
At the beginning of this thesis in Section 1.5, I posed several questions concerning the action
mode of daptomycin and the molecular basis of resistance to it. To answer these questions,
three projects were designed and carried out that were described in the preceding chapters.
The findings from these projects will be summarized here.
Daptomycin’s bactericidal effect has been proposed to involve three steps: membrane bind-
ing, oligomerization, and membrane depolarization. Previous studies had shown that in the
presence of a physiological level of Ca++, daptomycin will only bind to and oligomerize on
membranes containing PG.i Ca++ and PG are required both for oligomerization and for the
bactericidal effect, which suggested that oligomerization is important for antibacterial activity.
In Chapter 2, we used the lipopeptide antibiotic CB-182,362, which is very similar to dap-
tomycin in terms of structure and antibacterial activity. We showed that CB-182,362 can inde-
pendently form oligomers on susceptible artificial and bacterial membranes, and moreover that
iDaptomycin binds to membranes containing PC only or PC and CL, but only at non-physiologically high
calcium concentrations; but there is no oligomer formation on these membranes.
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it can also form stable hybrid oligomers when mixed with daptomycin. We then demonstrated
that, within such hybrid oligomers, daptomycin and CB-182,362 exercise mutual inhibition.
This finding indirectly shows that oligomerization is indeed an integral part of the bactericidal
action mode. If it were not, that is, if each subunit of the oligomer exercised its antibacte-
rial effect without requiring any cooperation from the neighbouring ones, the combination of
daptomycin and CB-182,462 should act in a strictly additive fashion, and the reduced specific
activity of hybrid oligomers relative to homogeneous ones could not be explained.
The mutual inhibition of the two compounds implies that at least some of the hybrid oligo-
mers are inactive. The subunits of these inactive hybrids must be trapped within a non-func-
tional structure. It seems possible that the inactive conformation resembles a transient stage in
the formation of the regular, active oligomer; however, this cannot be proven with the available
data.
In the current model of daptomycin action, the step following oligomerization is pore for-
mation. Previous studies have shown daptomycin’s activity is correlated with membrane de-
polarization, which has been hypothetically attributed to K+ leakage. However, selective K+
leakage should cause hyperpolarization rather than depolarization, since this ion is more con-
centrated inside the cell than outside. One would therefore expect that ions other than K+ can
also pass through the daptomycin pores. Before our work, the selectivity of the pore had not
been systematically studied.
In Chapter 3, we showed that a liposome model can be used to detect and characterize
the permeability properties of the daptomycin pores. We found that daptomycin indeed forms
discrete pores on PG-containing liposomes. These pores have the highest permeabilities for
Na+, K+, and other alkali metal ions. The rate of permeation is approximately twice lower for
Mg++, and yet lower again for the organic cations choline and hexamethonium. Anions like
Cl– and the zwitterion cysteine are excluded. These findings indicate the daptomycin pores are
selective for cations, and the permeability for these cations is limited by their sizes.
These findings also complement previous in vivo observations and suggest that the observed
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depolarization of bacterial cell membrane is mainly caused by the influx of Na+. The quanti-
tative analysis showed the average conductivity of daptomycin pore is very low, several orders
of magnitude lower than that of gramicidin. In comparison to daptomycin’s rapid bactericidal
activity, it is possible that only some of the oligomers function as active pores, suggesting the
possibility that pore-formation is only one of the several contributing factors to daptomycin’s
antibacterial activities.
An increased activity of cardiolipin synthesis has been observed in resistant Enterococcus
strains. The exact role of cardiolipin in the resistance mechanism is not yet understood. The
findings from Chapters 2 and 3 have paved the way for us to test the effect of cardiolipin in
each step of the proposed mechanism of action.
In Chapter 4, 10 or 20 molar % of CL was included in PG-containing model liposomes.
Fluorescence studies showed that the binding and oligomerization of daptomycin on these
membranes were not inhibited, but the membrane permeabilization for cations was completely
abolished. This suggested that the oligomers formed on CL-containing membranes are not
active.
The inactive and active oligomers were found different in both size and distribution across
the membrane leaflets. A FRET-based technique was applied to estimate the subunit numbers.
On the CL-containing liposomes, each oligomer comprises approximately four daptomycin
molecules, whereas on the susceptible membranes, this number is nearly twice as high.
The membrane-impermeant fluorescence quencher dithionite was used to assess the distri-
bution of membrane-bound NBD-daptomycin. On CL-containing liposomes, almost all of the
fluorescence signal was quenched right away, indicating the oligomers were confined to the
outer leaflet of the membrane. In contrast, on the susceptible liposomes, only about half of
the NBD-daptomycin was subject to immediate quenching, indicating that membrane-bound
daptomycin was evenly distributed on both inner and outer leaflets. These findings revealed
that cardiolipin inhibited the membrane translocation of daptomycin.
To sum up all the findings, a refined model for the molecular action mode of daptomycin
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was proposed. Monomeric daptomycin first binds to PG on the outer leaflet of membrane in
the presence of Ca++. Then, four bound monomers form a tetramer before being translocated
across the membrane to the inner leaflet. Finally, two tetramers on the opposite leaflets line
up to form a octameric ion pore. The presence of CL prevents the membrane translocation for
tetramer and the ultimate pore formation.
5.2 FUTURE WORK
5.2.1 Solid-state NMR for daptomycin pore structure
As demonstrated by the fluorescence studies presented in chapters 2 and 4, the formation of
oligomers with an accurate and intact structure is critical for daptomycin’s bactericidal activity
and ability to permeabilize the membrane. In order to better understand the mechanism of pore
formation, high-resolution structures would be very helpful. Fluorescence studies alone cannot
provide such high-resolution structures. NMR studies in solution have been attempted, but this
approach could not provide data of sufficient quality, due to certain experimental limitations,
such as sample aggregation. Preliminary results suggest that solid-state NMR may be an option
to circumvent these limitations.
5.2.2 Mechanism of resistance caused by lysyl-PG
An increase of CL and lysyl-PG content in cell membrane has been linked to the daptomycin
resistance by many studies. We have shown in Chapter 4 that CL has a very specific way to
prevent membrane permeabilization. With lysyl-PG, this has not been studied; it remains to be
seen whether or not resistance can be demonstrated in a liposome model, and if so, which step
is inhibited. It is even possible that additional aspects of the action mode may be discovered,
just as turned out to be the case with CL.
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Figure 5.1 Structure of a synthetic daptomycin dimer. Two peptide head groups are linked by one
long bivalent acyl tail.
5.2.3 Interaction between daptomycin and the bacterial cell wall
Since oligomer formation is important for daptomycin’s activity, one might expect that tether-
ing together daptomycin molecules to dimers or larger oligomers might increase the its antibac-
terial activity. Recently, a daptomycin dimer (Figure 5.1) has been synthesized by Dr. Scott
Taylor’s group. The dimer comprises two daptomycin peptide groups that are linked by a long
bivalent acyl tether. During initial tests, this compound showed no antibacterial activity. How-
ever, it showed very similar characteristics to native daptomycin in terms of ion permeability
through liposomal membranes. These preliminary observations raise the question whether the
dimer may be too big to traverse the cell wall, and so be unable to reach its intended target.
Note that this relates to the previously discussed hypothesis that resistance may be caused by
thickened cell wall (see Section 1.4.4). To verify this, an antibacterial activity test could be
carried out on protoplast cells, which lack a cell wall.
5.2.4 Quantitative analysis of membrane binding and oligomerization
The binding and oligomerization of daptomycin have mostly been described at a qualitative
level. The ability to quantitatively monitor these steps can offer a more in-depth understand-
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ing of interaction daptomycin with lipids, and also between the subunits within the oligo-
mer. Steady-state and time-resolved fluorescence analysis of pyrene excimer formation has
been widely used to characterize non-covalent interactions within and between polymers.54, 55
Due to the spectral overlap between the emission of pyrene and the absorbance of kynure-
nine, pyrene-labeled daptomycin is not suitable for such studies, since pyrene excitation is lost
through intramolecular FRET. However, the daptomycin-related lipopeptide A54145 lacks a
kynurenine residue and can therefore be used in pyrene-based fluorescence experiments. The
excimer fluorescence of this compound can provide insight into daptomycin and other mem-
brane bound peptide oligomers. Stopped-flow fluorescence experiments can also be used as a
supplementary approach.
5.2.5 Potentials with synthetic daptomycin analogues
Recently, Lohani, Taylor, and colleagues have synthesized daptomycin and several analogues
entirely using solid-phase based method (see Section 1.4.1.4), which has shown the potential
to produce a large library of daptomycin analogues. In their studies, the activity of analogues
that contain amino acid substitutions at position 12 and 13 (Figure 5.2) were assessed. The
analogue containing Glu-12 instead of MeGlu-12 was found less (approximately 8-fold) ac-
tive than daptomycin, which confirms the importance of methyl group for activity as had been
shown by earlier studies.77, 152, 153 The analogue with changed stereochemistry at the methyl
group (Dap-(2S,3S)-MeGlu-12) was found much less (approximately 40-fold) than the native
daptomycin (Dap-(2S,3R)MeGlu-12), which shows the stereochemistry of methyl group also
could significantly affect activity. Interestingly, the analogue containing double substitutions
(Glu-12,Trp-13) has the similar activity level as daptomycin. Whereas another double substi-
tuted analogue (Glu-12,Tyr-13) is about 40-fold less active than daptomycin. Future studies
on these analogues with membrane models could potentially reveal more details in daptomy-
cin’s structure-function relationships. The development of total synthesis can also facilitate
106
5 Summary and future work
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Figure 5.2 Structures of daptomycin and analogues. The analogues contain amino acid substitu-
tions at position 12 and 13 as pointed by arrows.
the search for analogues with improved activity, possibly the ones that are unaffected by lung
surfactant183 and are still safe for clinical use.
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